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ABSTRACT 
 
Avian HEV was first isolated in chickens from the USA that had hepatitis-
splenomegaly syndrome in 2001. Based on genetic identity and genomic organization, avian 
HEV has been classified into the genus Hepevirus, family Hepeviridae, which also includes 
human and swine HEVs. Avian HEV ORF2 protein was predicted to have common antigenic 
epitopes shared by avian, human and swine HEV, but its detailed antigenic epitope 
composition and protectivity have not been investigated. Vertical transmission of avian HEV 
in chickens also remains to be evaluated. 
To map HEV common and non-common epitopes on avian HEV ORF2 protein, nine 
synthetic peptides from the predicted four antigenic domains of the avian HEV ORF2 protein 
were synthesized and corresponding rabbit anti-peptide antisera were generated. With the use 
of recombinant ORF2 proteins, convalescent pig and chicken antisera, peptides and anti-
peptide rabbit sera, at least one epitope in domain II that is unique to avian HEV, one epitope 
in domain I that is common to avian, human and swine HEVs, and one epitope in domain IV 
that is shared between avian and human HEVs were identified.  
To determine if the capsid ORF2 protein of avian HEV can be protective and used as 
vaccine, twenty chickens were immunized with purified recombinant avian HEV ORF2 
protein with aluminum as adjuvant, and another twenty chickens were mock immunized with 
KLH precipitated in aluminum. After challenge, all the tested mock-immunized control 
chickens developed typical avian HEV infection but not in the tested chickens immunized 
with avian HEV ORF2 protein.  
 vi  
 
To identify neutralizing epitopes on avian HEV ORF2 protein, four Mabs (7B2, 1E11, 
10A2, 5G10) against this protein were generated and characterized. 1E11, 10A2 and 5G10 
were shown to bind to bona fide avian HEV particles in vitro, and partially neutralize virus in 
an animal based neutralization assay. The corresponding neutralization epiotpes were further 
localized by Western blot with the use of five avian HEV ORF2 recombinant proteins.  
Avian HEV was detected in egg white samples. Avian HEV contained in egg white 
was infectious as evidenced by viriema, fecal virus shedding and seroconversions in the 
chickens inoculated with avian HEV PCR positive egg white, but not in PCR negative egg 
white inoculated chickens. However, vertical transmission of avian HEV in chickens was not 
proved.  
The present studies pave the way for future avian HEV vaccine design and the 
development of differential immunoassays for the diagnosis of HEV cross-species infection. 
The results also implicate avian HEV infection in chicken could be a model system for 
studying HEV viral immune response, but not for studying HEV vertical transmission.    
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CHAPTER 1.  GENERAL INTRODUCTION 
Introduction 
Hepatitis E virus (HEV) causes frequent endemic and rare epidemic outbreaks of 
acute hepatitis E disease in humans in many developing countries [1, 2]. Disease caused by 
HEV results in a mortality rate of about 1% in general, but in pregnant women it can reach up 
to 20 % due to unknown reasons [3]. Recently, increasing sporadic cases of indigenous acute 
hepatitis E have been reported in industrialized countries [4-12], in addition to those 
associated with travel to endemic areas [13-16]. Anti-HEV antibodies have also been found 
in up to 20% of healthy individuals in these non-endemic countries [17]. Thus, HEV 
infection is probably more prevalent than previously estimated.  
Anti-human HEV antibodies were detected in multiple animal species [18-23]. 
However, to date, only two animal stains of HEV, swine HEV and avian HEV, have been 
isolated and well characterized [24, 25]. Swine HEV doesn’t cause clinic disease in pigs [26-
28], but can cross infect humans by foodborne transmission [12, 29, 30]. Avian HEV was
 
first isolated in the United States from chickens with hepatitis-splenomegaly
 
(HS) syndrome 
[25], an emerging chicken disease in North America that is characterized
 
by increased 
mortality in broiler breeder hens and laying hens
 
between 30 and 72 weeks of age as well
 
as 
up to a 20% drop in egg production [25, 31-33]. This disease was partially reproduced in SPF 
chickens by inoculation with avian HEV [34]. Avian HEV failed to infect non-human 
primates [35], but it can infect turkeys and swine [36, 37]. Based on genetic identity and 
genomic organization, avian HEV has been classified into the genus Hepevirus, family 
Hepeviridae, which also includes human and swine HEVs [38]. 
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Three partially overlapping open reading frames (ORFs) have been identified in the 
HEV genome. Antibodies to all three ORF proteins appear following infection [17, 39, 40], 
but anti-ORF2 protein antibody is the one that can be most reliably detected in infected 
patients and animals [41-43]. Human HEV ORF2 recombinant protein is thus the major 
target antigen used in HEV serological assays [44-49]. However, it has been shown that the 
avian HEV recombinant ORF2 protein can be equally recognized by anti-sera rainsed against 
avian, swine and human HEVs and anti-avian HEV chicken sera can react with recombinant 
ORF2 proteins of avian, human and swine HEV [50]. Swine HEV ORF2 protein can also 
react with anti-human HEV sera and vice versa [51]. Four major antigenic domains at the C 
terminal 268 amino acid residues of avian HEV ORF2 protein were predicted based on the 
corresponding region of human HEV ORF2 proteins [50], but whether epitopes in these 
domains are shared with human and swine HEVs or unique to avian HEV is not known. 
Human HEV ORF2 protein is the major HEV viral antigen that can elicit protective 
humoral immunity [52-55]. Several studies have demonstrated that immunization of 
truncated recombinant human HEV ORF2 protein can prevent infection by inducing efficient 
neutralizing antibodies [47, 55-59]. Avian HEV is genetically and antigenically related to 
human HEV [35, 50]. However, it is not yet known if avian HEV ORF2 protein can provide 
protection against avian HEV infection and if it contains neutralization epitopes that can 
contribute to the protection. 
In addition to the primary fecal-oral route of transmission, human HEV can also be 
vertically transmitted from infected mothers to their fetuses resulting in significant perinatal 
morbidity and mortality [60-64]. Although rhesus monkeys are frequently used as an animal 
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model for HEV infectivity studies, pregnant monkeys failed to transmit virus to their 
offspring [65]. Attempts to demonstrate vertical transmission of swine HEV from pregnant 
gilt was also unsuccessful [66]. Therefore, it would be of interest to determine if avian HEV 
can be vertically transmitted and be used as a small animal model for studying some aspects 
of HEV vertical pathogenesis. 
In order to address the problems as described above, four major objectives were 
developed as followed:  
1. Identify antigenic epitopes on avian HEV ORF2 protein that are unique to avian 
HEV in addition to epitopes common to human and/or swine HEVs.  
2. Evaluate the protective ability of a recombinant avian HEV ORF2 protein. 
3. Map neutralization epitopes on the avian HEV ORF2 protein. 
4. Investigate the possibility of vertical transmission of avian HEV in chickens.  
In the first study, we defined HEV common epitopes and avian HEV unique epitopes 
on the avian HEV capsid protein using synthetic peptides, anti-peptide sera, ORF2 proteins of 
avian, human and swine HEVs and anti-HEV convalescent sera. In the second study, 
chickens were immunized with avian HEV ORF2 protein and challenged with avian HEV, 
proving that the recombinant avian HEV ORF2 protein can provide protection against avian 
HEV infection. In the third study, two independent neutralizing epitopes were mapped on the 
avian HEV ORF2 protein using monoclonal antibodies (Mabs) and serial truncated avian 
HEV ORF2 fragment proteins. In the fourth study, we detected avian HEV in egg whites and 
demonstrated that egg white avian HEV is infectious. However, we were unable to confirm 
that avian HEV was able to be transmited vertically. 
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Overall, these results of these studies pave the way for future avian HEV vaccine 
design studies and the development of differential immunoassays for the diagnosis of cross-
species HEV infection. Our results also demonstrated that chicken can be a small animal 
model for HEV immunological studies in addition to its current use for HEV pathogenesis 
studies, however, this model may not be suitable for HEV vertical transmission studies.    
Dissertation organization  
This dissertation is written in the alternative format and organized into seven 
chapters. The first chapter contains introduction of research background, statement of 
problems, general objectives and brief research results. The second chapter is a literature 
review. The next four chapters are four manuscripts that have been published, accepted, or 
submitted to journals. Each of these chapters is presented in the form prepared for 
publication. The doctoral candidate has actively participated in project writing, experiment 
performance, data collection and analysis, and is the senior author of all the four research 
papers. The first research paper titled “Identification of B-cell epitopes in the capsid protein 
of avian hepatitis E virus (avian HEV) that are common to human and swine HEVs or unique 
to avian HEV” was published in the Journal of General Virology, 2006, 87: 217-213.  The 
second research paper, “Protection of chickens against avian hepatitis E virus (avian HEV) 
infection by immunization with recombinant avian HEV capsid protein”, was submitted to 
and accepted by Vaccine. The third research paper, “Identification of two neutralization 
epitopes on the capsid protein of an avian strain of hepatitis E virus by epitope mapping” was 
submitted to Journal of Virology. Chapter 6 is entitled “Egg whites from eggs of chickens 
experimentally infected with avian hepatitis E virus contain infectious virus but evidence of 
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complete vertical transmission is lacking”. It is the fourth research paper that was submitted 
to Journal of General Virology. Chapter 7 is the general conclusions and discussions for these 
studies as described in this dissertation. Recommendation for future research is also included 
in the final chapter. References are listed at the end of each chapter. 
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CHAPTER 2. LITERATURE REVIEW 
Introduction 
Hepatitis E virus (HEV) is the etiological agent of hepatitis E, an acute disease that is 
primarily transmitted via the fecal–oral route. The disease has low mortality rates in the 
general population, but in pregnant women, it can result in high mortality rate, reaching 
approximately 20% [1]. The discovery of anti-HEV antibodies in animals and birds and the 
isolation and characterization of two animal HEVs, swine HEV and avian HEV [2, 3] has 
generated questions regarding the zoonotic potential of these viruses. Knowledge of human 
HEV generally exceeds what is known about animal HEV, but some aspects of research on 
animal HEV can provide model systems for human HEV study. In this review, the natural 
history, epidemiology, disease and pathogenesis, virology, immunology, diagnosis and 
prevention of human HEV are discussed. Brief reviews of swine HEV and avian HEV based 
on limited available data are also presented. A general summary of human and animal HEVs 
is provided at the end.   
Natural history 
Hepatitis E, previously known as an enterically transmitted non-A, non-B hepatitis, 
was first recognized in the 1980s when sera from affected patients in a waterborne viral 
hepatitis epidemic during 1955–56 in Delhi, India were found to lack serological markers of 
acute hepatitis A and B [4-6].   
The first proof of the existence of a new viral hepatitis agent was obtained in 1983, 
when spherical 27-30 nm virus-like particles were visualized by immune electron microscopy 
in feces collected from a volunteer who was infected with stool material from patients with 
 15  
 
suspected enterically transmitted non-A, non-B hepatitis [7]. This infectious virus was named 
as HEV in 1988 [8]. The partial genome of HEV was cloned in 1990 [9] and the full-length 
sequence was determined subsequently [10]. The sequencing results of the whole viral 
genome finally confirmed that HEV was a new virus.  
The disease was also successfully transmitted to non-human primates, including 
different species of monkeys and chimpanzees [7, 11-14]. Non-human primates have thus 
been used as invaluable vectors for maintaining and passing HEV in vivo, since a cell culture 
system for efficient propagation of HEV is lacking.  
Epidemiology 
Prevalence  
HEV causes epidemics of viral hepatitis in developing countries on all continents, 
often involving very large numbers of patients [15]. Apart from the 1955–56 New Delhi 
epidemic, other notable epidemics include: Kirgiz Republic, Soviet Union (1955–1956, 10 
000 cases); Kathmandu Valley, Nepal (1973–1974, 10 000 cases); Mandalay, Myanmar 
(1976–1977, 20 000 cases); Kashmir, India (1978–1982, 52 000 cases); Xinjiang, China 
(1986–1988, 120 000 cases); and Kanpur, India (1991, 79 000 cases) and the Greater Darfur 
region, Sudan (2004, 5000 cases) [16, 17]. 
Sporadic cases of acute hepatitis E have also been reported in patients in developed 
countries such as Australia, France, Israel, The Netherlands, Spain, Italy, UK, Japan and USA 
[15, 18-24]. These occurrences are mainly associated with travel to endemic areas. However, 
recently, increasing cases of indigenous acute hepatitis E in these countries have also been 
reported [25-30]. Consumption of raw or undercooked shellfish, pig liver, deer and boar meat 
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are linked to these cases [25-27], but in some cases, the source of the infection remains 
unknown [28-30]. Anti-HEV antibodies have also been found in a significant number (up to 
20% in some areas) of healthy individuals in areas previously thought to have low infection 
rates [31]. HEV infection is thus probably more prevalent in industrialized countries than 
previously estimated.  
Transmission  
HEV is transmitted primarily through the fecal–oral route via contaminated drinking 
water [32]. The disease is found most frequently in regions, where fecal contamination of the 
drinking water supply is common [33]. Food-borne outbreaks have been documented and 
believed to be the source of sporadic cases in some endemic and non-endemic areas [25-27, 
34]. The occurrence of sporadic HEV infections in humans may maintain transmission during 
inter-epidemic periods [34]. Vertical transmission of HEV from infected mothers to their 
newborns has also been documented and causes significant perinatal morbidity and mortality 
[35-38]. Three cases of indigenous HEV infection via blood transfusion have been reported 
in the UK and Japan recently [39-41], suggesting hepatitis E should now be considered when 
investigating post-transfusion hepatitis in addition to hepatitis B and C [39]. However, 
person-to-person transmission of HEV is uncommon as household contact with HEV-
infected patients does not appear to increase risk [32]  
Zoonotic infection 
Anti-HEV antibodies have been detected in a number of animal species including 
cattle, pigs, chickens, sheep, goats, nonhuman primates, deer, rodents, mongooses and 
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donkeys [13, 42-46]. However, to date, only two animal strains of HEVs, swine HEV and 
avian HEV, have been isolated and well characterized [3, 4].   
Hepatitis E is a zoonotic in nature [47]. Cross-species infection by swine and human 
HEVs has been demonstrated. A human HEV strain has been shown to infect specific-
pathogen-free (SPF)
 
pigs and a swine HEV strain infected nonhuman primates [48, 49]. 
Increased risk of zoonotic HEV infection was reported in swine veterinarians and other pig 
workers, especially in countries where HEV is considered rare, such as in the USA and 
Taiwan [50]. Swine and their waste have been concluded as important sources of infection 
for swine veterinarians and farmers [50-52]. However,
 
the high prevalence of anti-HEV 
antibodies in human
 
populations not at apparent risk of exposure to swine HEV suggests
 
that 
other sources of exposure may exist, in addition to swine HEV [50].  
Most recent direct evidence of zoonotic HEV transmission came from reports from 
Japan, where several cases of hepatitis E occurred after patients consumed raw or 
undercooked livers, meats from HEV infected pigs, deer or wild boars [25-27]. The 
sequenced virus from the patients were identical or near identical to the viruses recovered 
from these animal foods. 
Although one report showed that avian HEV failed to infect rhesus monkeys [53], it 
has been proven that avian HEV can infect turkeys [54]. And most recently, it was shown that 
pigs can be infected with avian HEV [55], indicating that avian HEV has the ability to adapt 
in some mammalian animals for replication and evolution. Currently, there is no direct 
evidence that avian HEV from chickens and avian HEV recovered from pigs can infect 
humans, however, avian HEV is still of possible zoonotic concern.  
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Disease and pathogenesis 
Disease 
Hepatitis E is a self-limiting disease with severity varying from subclinical infection 
to fulminant hepatitis [32, 56]. The clinical symptoms include jaundice, anorexia, 
hepatomegaly, abdominal pain and tenderness, nausea, vomiting and fever [32, 56-58]. HEV 
is usually present in the bloodstream for 1 to 2 weeks and disappears before the onset of 
clinical symptoms and fecal virus shedding also occurs during the incubation period and early 
acute phase of disease [33, 59]. However, in some infected patients, protracted viremia has 
been observed [60]. Symptomatic HEV infection is generally seen in middle-aged adults [32, 
33]. Fulminant hepatitis E may develop and cause a low mortality rate of about 1% in the 
general population [32, 33]. However, the mortality rate can reach up to 20% in infected 
preganant women during their 3rd trimester of pregnancy with unknown reason [36, 61-63]. 
There is no chronic phase of HEV infection [32, 34]. 
Pathogenesis 
Most of our understanding of HEV pathogenesis came from experimental studies in 
non-human primates and human volunteers [64]. After the entry of HEV into the host via the 
oral route, the primary site of replication is probably in the intestinal tract. It is still not clear 
how the virus reaches the liver, but it is presumably through the hepatic portal vein [16, 65]. 
HEV then replicates in the cytoplasm of hepatocytes before being released into the bile and 
bloodstream. Liver pathology can be detected one or two weeks after virus replication, and is 
characterized by portal triaditis, cholestasis, lobular inflammation and degeneration of the 
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liver to varying degrees [16, 66-68]. Hepatic apoptosis and focal necrosis can be seen in 
livers with only mild inflammation [66, 67].  
Serum biochemical change is strictly correlated with liver pathology. Due to the 
hepatocellular damage, serum alanine aminotransferase (ALT) increases dramatically at the 
time the virus is detected and lasts for three to four weeks [16, 69]. ALT is the representative 
enzyme used for the diagnosis of HEV induced acute hepatitis, although it is not a disease 
specific marker [66, 70]. Given that liver pathology is typically confined to small foci, it 
seems that the disease lesions are widespread, in order for them to be sampled by needle 
biopsy and detected. It also appears that the dissermination of the lesions is required to cause 
the sudden rise of ALT [71]. The fact that the onset of ALT elevation and the presence of 
histopathological changes in the liver generally correspond with the detection of anti-HEV 
antibody in sera and the decreasing levels of HEV antigen in hepatocytes suggests that HEV 
might not directly cause cytopathic changes and its pathogenesis might be mediated by the 
host immune responses [72]. 
To explain the pathogenesis of fulminant hepatitis E in pregnancy, one hypothesis put 
forward [72] proposes that the liver sinusoidal cells, particularly the Kupffer cells, are 
damaged by HEV, diminishing the ability of these cells to protect hepatocytes against 
endotoxins that originate from Gram-negative bacteria found in the intestinal tract. The 
enhanced sensitivity of pregnant women to such an endotoxin-mediated effect is well 
recognized and might explain the strikingly high mortality of hepatitis E in pregnancy [72]. 
However, the validity of this hypothesis and the precise underlying cellular and molecular 
mechanisms haven’t been confirmed.  
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Virology 
Molecular Characteristics 
HEV has a single-stranded, positive-sense RNA genome that is approximately 7.2 kb 
in size and consists of a short 5′-untranslated region (UTR), three partially overlapping open 
reading frames (ORFs) and a short 3′-UTR terminated by a poly(A) tract [73]. Recently, HEV 
was reclassified as the sole member of the genus Hepevirus in the family Hepeviridae [74]. 
Although the whole genome of HEV was sequenced more than 10 years ago [10], little is 
known about viral replication and expression in vivo, as HEV has not been grown 
reproducibly and  efficiently in cell culture. Molecular biology study of HEV has focused on 
the three ORFs with the use of recombinant technology and infectious cDNA clone strategy 
[32, 75] 
ORF1 encodes one polyprotein consisting of non-structural proteins that are 
potentially involved in viral genome replication and viral protein processing. This is 
suggested due to the presence of sequence motifs characteristic of viral methyltransferases, 
papain-like cysteineproteases, helicases and RNA-dependent RNA polymerases in the ORF1 
gene [16, 76, 77]. In addition, ORF1 has two regions called Y and X domains of unknown 
function. Most recently, it has been shown that processing of ORF1 polyprotein is dependent 
upon a cysteine protease [78]. 
ORF2 encodes a capsid protein of 660 amino acids (aa) that may contain three 
glycosylation sites. The full-length ORF2 protein can be expressed as a 72 kDa protein in 
cultured insect cells, but quickly degrades into several subunits with the sizes of 53 kDa, 55 
kDa and 63 kDa by non-viral proteolytic enzymes [79, 80]. However, the size of the ORF2 
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protein in native virons is not known [81]. In vitro assays suggest that the ORF2 protein is 
co-translationally translocated across the endoplastic reticulum and is expressed 
intracellularly as well as on the cell surface [82]. The ORF2 protein contains important 
epitopes near the carboxyl ends that can induce neutralizing antibodies and has been the 
focus of vaccine development [83].  
ORF3 is located at the end of ORF1 and overlaps with ORF1 at its 5' end by only 1 
nucleotide, and overlaps with ORF2 at its 3' end by 328 nucleotides. It encodes a 123 aa 
protein that is expressed intracellularly and probably associates with the liver cell 
cytoskeleton [84] as well as facilitating virus assembly and release by interacting with 
nonglysolated ORF2 protein [85]. ORF3 may also be involved in signal transduction [86, 87]. 
Interestingly, it has been recently shown that the ORF3 protein is required for HEV 
infectivity in vivo [88], but not for infection or production of infectious virus in vitro [75].  
Genotypes  
Based on phylogenetic analysis of the full-length genomes of HEV isolates, four 
major genotypes were grouped that also differ with respect to
 
geographic distribution, host 
range,
 
and pattern of infection [74, 89, 90]. Genotype
 
1 is prevalent in
 
Asia and Africa [11, 
91-93] as represented by Sar-55 from Pakistan. Virus in this genotype has been isolated
 
only 
from humans and
 
has been associated with
 
large waterborne outbreaks. Genotype 2
 
contains a 
single strain of HEV isolated from a
 
fecal sample collected during
 
an outbreak of non-A,
 
non-
B hepatitis in Mexico
 
in 1986 [94]. Genotype
 
3 is prevalent worldwide [89]. Viruses in this 
genotype that were isolated from
 
animals (swine, deer and boar) and humans in
 
the United 
States [95],
 
the United Kingdom [96],
 
and Japan [26, 97, 98]. Viruses of group 3 are
 
closely 
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genetically related, suggesting the possibility of zoonotic transmission. Indeed, HEVs from 
swine, deer and boar in this genotype have caused sporadic cases
 
of
 
acute hepatitis in humans 
in industrialized countries, like Japan. Genotype 4 includes recent variant isolates from 
China, Japan,
 
India, Indonesia,
 
and Vietnam [89]. These viruses are prevalent mainly in 
humans and swine, but have also been reported in wild boars [99]. Viruses in this genotype 
are also associated with sporadic
 
cases and food-borne outbreaks.  
Although the sequences of HEV strains are very heterogeneic, it appears that all HEV 
isolates to date belong to a single serotype [32]. Different genotypes can’t be distinguished 
serologically and
 
are also cross-protective [32, 100].  
Immunology 
Antibody in HEV immunity 
During acute HEV infection, anti-HEV IgM precedes IgG production by a few days, 
appears during early phase of clinical illness and continues to be detectable up to 3 months 
[16]. Anti-HEV IgA can be simultaneously detected with IgM in sera during acute phase of 
infection [101]. However, the duration of anti-HEV IgA in serum is longer than that of anti-
HEV IgM [102]. The production and role of mucosal anti-HEV IgA in infected hosts is 
poorly documented in the literature, although immunization of recombinant ORF2 protein 
can elicit an intestinal IgA response [103]. Anti-HEV IgG follows shortly after detection of 
IgM and peaks several weeks later, and can be detected for months and years after infection 
[104, 105]. Neutralization antibody plays a crucial role against HEV infection, but its 
dynamics in infected humans or animals hasn’t been investigated. Little is known about the 
anti-HEV cellular immunity. 
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Both active and passive immunization studies suggest that humoral immunity is the 
effective protective mechanism in HEV infection
 
[66, 106-108] and antibody to the ORF2 
protein is sufficient to confer protection [83, 109]. Rhesus monkeys immunized with 
truncated recombinant human HEV ORF2 protein expressed in insect cells can prevent HEV 
infection and the development of hepatitis [71, 110, 111]. Further, immunization can protect 
monkeys not only from homologous challenge but heterologous challenge as well [100, 110, 
112, 113]. Broadly reactive anti-HEV neutralizing antibodies are induced in infected patients 
or immunized animals and can explain the heterologous protection [114, 115].  
Antigenic epitopes in ORF2 capsid protein 
The antigenic epitopes of the 660-aa human HEV ORF2 capsid proteins have been 
extensively examined with synthetic peptides and recombinant ORF2 proteins [116-119]. 
ORF2 antigenic epitopes are found principally located at the N and C termini, but C terminal 
epitopes are most important for protective immunity [118, 120, 121]. The identification of a 
major broadly protective neutralizing epitope on the C terminal part of human HEV Sar-55 
ORF2 capsid protein [83, 114, 122] further supported this conclusion.  
A full length recombinant ORF2 protein was strongly reactive with acute phase sera 
from HEV infected macaques and patients, but was poorly reactive with convalescent sera 
[117]. A partial recombinant ORF2 protein (aa394-660) was strongly reactive with both acute 
and convalescent phase sera and extension of this recombinant protein toward the N-terminus 
led to a progressive loss of convalescent phase reactivity [117, 123]. The difference in the 
reactivity with acute phase serum and convalescent serum between full length and partial 
ORF2 proteins clearly showed that the antigenic epitope profile of partial ORF2 proteins 
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differs and the use of partial ORF2 protein may be even better for both HEV diagnosis and 
vaccine development. 
Diagnosis and Prevention 
Hepatitis E can not be clinically distinguished from other types of acute viral 
hepatitis [124]. If outbreaks of waterborne hepatitis occur in developing countries, especially 
if the disease is more severe in pregnant women, or if hepatitis A is not the causative agent, 
hepatitis E should be considered [125]. The diagnosis of acute or fulminant hepatitis E is 
based on
 
detection of the HEV genome in serum or feces by PCR assays, including RT-PCR, 
nested RT-PCR and recently developed real-time PCR [126-130] or detection of newly 
elicited anti-HEV IgA and IgM by ELISA by a commercial kit (Genelabs Technologies, 
Singapore) or in-house assay [101, 131, 132]. Detection of anti-HEV IgG by ELISA is most 
commonly used for the diagnosis of recovered HEV infection and serological HEV 
surveillance [133-136]. Immunofluorescent assays can be used to detect HEV antigen in liver 
and other tissues [137]. Detection of HEV particles in stool specimens by immune electron 
microscopy is infrequently used [33]. Target antigens in those serological assays are either 
recombinant HEV ORF2 proteins or synthetic HEV peptides that containing 
immunodominant epitopes of the ORF2 proteins [138-140]. One drawback of current 
serological diagnosis is that it can’t differentiate potential zoonotic HEV infection, as human 
HEV ORF2 proteins can react with anti-human, swine and avian HEV sera [141-143]. 
No therapeutic compounds or commercial vaccines for HEV are available yet, 
although one promising HEV subunit vaccine candidate, Sar-55 HEV recombinant ORF2 
protein vaccine, was developed at National Institutes of Health (Bethesda, MD, USA) and is 
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currently undergoing a phase II/III field trial in Nepal [110]. Prevention is the most effective 
approach against the disease. As HEV is mainly spread by the fecal-oral route, good personal 
hygiene, high quality standards for public water supplies and proper disposal of sanitary 
waste have resulted in a low prevalence of HEV infections in many developed countries [34]. 
Swine HEV 
Discovery and characterization  
The first swine HEV was isolated from an HEV-seropositive commercial herd in 
Midwestern USA [2] after the ability of human HEV to infect swine and the presence of anti-
HEV antibodies in swine was reported [144, 145]. The complete genomic sequence of swine 
HEV was determined and found to have a similar genomic organization to human HEV [2, 
146]. Since then, swine HEV has been detected in pigs throughout the world [69]. 
Approximately 70-100% nucleotide sequence identity is shared between swine and human 
HEV [2, 147-149]. The ubiquitous nature of swine HEV infection in pigs suggests that swine 
are reservoirs for HEV [47].  
Sequence comparison has shown that swine HEV isolates are also heterogeneic in 
different geographic regions and all isolates identified thus far belong to either genotype 3 or 
genotype 4 [52, 150]. Genotype 1 or 2 swine HEV haven’t been detected in pigs and attempts 
to infect pigs with genotype 1 (Sar-55) or genotype 2 (Mexico-14)
 
strain of human HEV have 
been unsuccessful [150, 151], suggesting genotype 1 or 2 swine HEV may not exist and 
genotype 1
 
and 2 HEVs are restricted to humans and are not zoonotic in nature [150]. Both 
genotype 3 and 4 swine HEVs are associated with sporadic
 
cases and food-borne outbreaks in
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human. However, since genotype 3
 
swine HEV is widely distributed,
 
evolution of virulent
 
strains from this genotype
 
would have more far-reaching
 
consequences [52]. 
Infection and disease 
Although swine HEV could be detected in different tissues of naturally infected pigs 
[152-154], unlike HEV infection in human, swine HEV infection in pigs does not cause 
clinical disease [48, 151]. In addition, unlike the high degree of vertical transmission of 
human HEV from mother to fetus, there was no vertical transmission of swine HEV and 
reproduction also appeared not to be affected [155]. As a result, swine HEV has limited use 
for HEV pathogenesis studies [156]. Currently, there is little or no demand for diagnostics or 
vaccination against swine HEV [69]. However, as more is learned about the zoonotic 
significance of swine HEV, this may change.  
Avian HEV 
Discovery and characterization 
A study conducted in Vietnam showed that antibodies to human HEV were prevalent 
in 44% of tested chickens, indicating that an HEV or an HEV-like agent infected chickens 
[43]. In 2001, the corresponding agent was isolated in the USA from chickens that had HS 
syndrome [3], an emerging disease
 
of chicken in North America [3, 157, 158]. Based on the 
similar genome organization of this novel chicken virus to and its genetic relatedness with 
mammalian HEVs (human and swine HEVs) [3, 53], it was designated avian hepatitis E virus 
(avian HEV) to distinguish it from mammalian HEVs. 
Electron microscopic examination revealed that avian HEV is also a non-enveloped 
virus of 30–35 nm in diameter, with similar size and morphology to human HEV [3]. Avian 
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HEV shares about 50% nucleotide sequence identity with mammalian HEVs over the 
complete genome, 48-51 % identity in ORF1, 46-48 % identity in ORF2 and only 29-34 % 
identity in ORF3 [3, 53]. Motifs in the putative functional domains of ORF1, such as the 
helicase and methyltransferase, were relatively conserved between avian HEV and 
mammalian HEVs, supporting the conclusion that avian HEV is a member of the genus 
Hepevirus [90].  
Avian HEV was found to share common antigenic epitopes in its capsid protein with 
mammalian HEVs [141, 143]. Therefore, avian HEV is not only genetically but also 
antigenically related to mammalian HEVs. However, the importance of these epitopes in anti-
avian HEV immune response hasn’t been studied yet. 
Like the mammalian HEVs, cell culture for avian HEV propagation is not available. 
The attempts to culture it in embryonated eggs failed in one study group [159]. But, very 
recently, Meng, et al [160] reported the success of propagation of this virus by intravenous 
(IV) inoculation of 100 GE of avian HEV into embryonated chicken eggs at 9 days of 
embryonated age. The recovered fecal virus collected from hatched chicks can reach a titer of 
10
6 
to 10
7 
GE/ml. Propagation of human and swine HEVs were also tried in this system, but 
was unsuccessful (X.-J. Meng, personal communication). 
Infection and disease 
Serological evidence has unequivocally shown that chickens are widely infected with 
avian HEV as 71% of flocks from five investigated states in USA were positive for avian 
HEV [161, 162]. Experimentally, avian HEV is also able to cross species barriers and infects 
turkeys and swine, although infected animals have not shown any clinical signs [54, 55]. The 
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HS syndrome was first reported in Canada in 1991 [158] and has since been recognized in the 
United States [157, 158]. This syndrome in US chickens is characterized by increased 
mortality, 20% drop in egg production in birds (primarily broiler breeders) from 30 to 72 
weeks of age, presence of an enlarged liver and spleen, regressive ovaries and red fluid in the 
abdomen [157], whereas young birds are more often asymptomatic or subclinical [54, 162].  
Avian HEV infection in chickens has been used as small animal model for HEV 
pathogenesis studies [156]. In experimental infection, typical liver lesions range from 
multifocal lesions to extensive necrosis and hemorrhage [156, 162]. Under field conditions, 
chickens are mostly subclinically infected, although sporadical HS syndrome has been 
inconsistently reproduced [156, 161]. It has been speculated that generation of sporadic 
disease may be dose-dependent or avian HEV infection, while an important factor,
 
is not the 
sole factor for the development of clinical HS
 
syndrome [156, 162]. Diagnosis is by 
observation of typical signs and lesions, and prevention is currently by thorough cleaning and 
disinfection after depletion of an affected flock [69]. 
Summary 
Current human HEV research is mainly focused on molecular mechanisms of 
pathogenesis, vaccines and zoonosis. Swine HEV continues to be considered as important 
sources for sporadic cases of zoonotic human hepatitis E and a potential concern for zoonotic 
HEV infection in xenotransplantation with pig organs. As avian HEV is a relatively new 
virus and difficult to propagate in vitro, several important aspects about this virus, including 
pathogenesis, virus circulation and evolution in field and the detailed host immune responses 
need to be investigated. Since a variety of animals could be infected by HEV or HEV-like 
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virus, which has the potential importance as an emerging animal pathogen for public health, 
it is necessary to continue to search for and characterize these viruses in animals. 
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CHAPTER 3. IDENTIFICATION OF B CELL EPITOPES IN THE CAPSID 
PROTEIN OF AVIAN HEPATITIS E VIRUS (AVIAN HEV) THAT ARE COMMON 
TO HUMAN AND SWINE HEVS AS WELL AS UNIQUE TO AVIAN HEV 
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Abstract  
Avian hepatitis E virus (avian HEV) was recently discovered
 
in chickens from the USA that 
had hepatitis–splenomegaly
 
(HS) syndrome. The complete genomic sequence of avian HEV 
shares
 
about 50 % nucleotide sequence identity with those of human
 
and swine HEVs. The 
open reading frame 2 (ORF2) protein of avian
 
HEV has been shown to cross-react with 
human and swine HEV ORF2
 
proteins, but the B-cell epitopes in the avian HEV ORF2 
protein
 
have not been identified. Nine synthetic peptides from the predicted
 
four antigenic 
domains of the avian HEV ORF2 protein were synthesized
 
and corresponding rabbit anti-
peptide antisera were generated.
 
Using recombinant ORF2 proteins, convalescent pig and 
chicken
 
antisera, peptides and anti-peptide rabbit sera, at least one
 
epitope at the C terminus 
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of domain II (possibly between aa
 
477–492) that is unique to avian HEV, one epitope in 
domain
 
I (aa 389–410) that is common to avian, human and swine
 
HEVs, and one or more 
epitopes in domain IV (aa 583–600)
 
that are shared between avian and human HEVs were 
identified.
 
Despite the sequence difference in ORF2 proteins between avian
 
and mammalian 
HEVs and similar ORF2 sequence between human and
 
swine HEV ORF2 proteins, rabbit 
antiserum against peptide 6
 
(aa 389–399) recognized only human HEV ORF2 protein, 
suggesting
 
complexity of the ORF2 antigenicity. The identification of these
 
B-cell epitopes in 
avian HEV ORF2 protein may be useful for
 
vaccine design and may lead to future 
development of immunoassays
 
for differential diagnosis of avian, swine and human HEV 
infections.
  
 
Introduction 
Hepatitis E virus (HEV) causes frequent endemic and rare epidemic outbreaks of 
acute hepatitis E in many developing countries. Sporadic cases of acute hepatitis E have also 
been reported in industrialized countries including the USA, Europe and Japan (Clemente-
Casares et al., 2003; Mansuy et al., 2004; Okamoto et al., 2003). HEV is transmitted by 
faecal contamination of water. Cross-species infection has been documented as human and 
swine HEV strains are genetically closely related, and experimental cross-species infection of 
swine HEV to a chimpanzee and human HEV to pigs has been demonstrated (Meng et al., 
1998, 2002; Meng, 2003; Halbur et al., 2001). It is now recognized that hepatitis E is a 
zoonosis, and pigs and rats are considered to be the reservoir for HEV (Hirano et al., 2003; 
Kabrane-Lazizi et al., 1999; Meng et al., 1997, 1999b; Meng, 2005).  
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Hepatitis–splenomegaly (HS) syndrome is an emerging disease
 
of chicken in North 
America (Haqshenas et al., 2001; Riddell,
 
1997; Ritchie & Riddell, 1991). Avian hepatitis E 
virus
 
(avian HEV) was isolated from chickens in the USA in 2001 (Haqshenas
 
et al., 2001) 
that had HS syndrome, and lesions characteristic
 
of HS syndrome have recently been 
reproduced in specific-pathogen-free
 
(SPF) chickens (Billam et al., 2005). A recent study 
indicated
 
that avian HEV is heterogenic and enzootic in chicken flocks
 
as some avian HEV 
strains spread subclinically among chickens
 
in the USA (Huang et al., 2002; Sun et al., 
2004a).
 
 
Avian HEV is a member of the genus Hepevirus (Emerson et al.,
 
2004), which also 
includes human and swine HEVs. Phylogenetic
 
analysis revealed that avian HEV represents a 
branch distinct
 
from human and swine HEVs (Huang et al., 2004). The genome of
 
mammalian HEV is approximately 7·2 kb in size and
 
contains three open reading frames 
(ORFs) (Emerson & Purcell,
 
2003). ORF1 encodes viral non-structural proteins, ORF2 
encodes
 
the putative capsid protein and ORF3 encodes a small protein
 
that may be involved 
in modulating cell signalling (Emerson
 
& Purcell, 2003; Meng et al., 1999a), suggesting a 
possible
 
role in host–virus interaction. The genome of avian HEV
 
is about 600 nt shorter than 
those of swine and human HEVs
 
(Huang et al., 2004). Humoral immune response is 
important for
 
protection, and the ORF2 capsid protein is immunogenic and is
 
thought to be 
responsible for the induction of humoral immune
 
responses (Zhang et al., 2001; Riddell et 
al., 2000). Thus,
 
the ORF2 capsid protein is the target of current vaccine design
 
and its 
recombinant proteins expressed either in Escherichia
 
coli or insect cells are used for 
evaluation of vaccine efficacy
 
(Purcell et al., 2003). It has been demonstrated that 
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chimpanzee
 
antibodies specific for linear epitopes in the ORF2 capsid protein
 
neutralized 
human HEV infection in rhesus monkeys (Schofield
 
et al., 2000, 2003).
 
 
The ORF2 gene of avian HEV shares approximately 48–49
 
% amino acid sequence 
identity with that of swine HEV and the
 
US2 and Sar-55 strains of human HEV (Haqshenas 
et al., 2002).
 
Four major antigenic domains at the C-terminal 268 aa residues
 
of capsid 
protein from avian, swine and human HEV were predicted
 
by Haqshenas et al. (2002) 
according to the methods of Kyte–Doolittle
 
and Welling using the MacVector computer 
program (Oxford Molecular)
 
and based on the hydrophilicity and antigenicity. Domain I is
 
most conserved among avian, human and swine HEVs, whereas domain
 
IV is more antigenic 
in avian HEV than in swine and human HEVs.
 
 
In the present study, we demonstrated that B-cell epitopes in
 
the antigenic domain I 
are shared among avian, human and swine
 
HEV capsid proteins, and that epitopes in domain 
IV are shared
 
between avian and human HEVs. However, epitopes in domain II
 
are unique to 
avian HEV.
 
 
Materials and Methods 
Production of recombinant avian HEV ORF2 protein. The expression, extraction 
and purification of ORF2 protein
 
were performed essentially as described previously 
(Haqshenas
 
et al., 2002) with the following modifications. After initial
 
purification by using 
His-Bind resin column (Novagen), the ORF2
 
protein was further purified by electroelution. 
Briefly, ORF2
 
inclusion body protein effluent in the elution buffer (Novagen)
 
suspension was 
mixed with the reducing Laemmli sample buffer
 
(Bio-Rad) and loaded onto 7·5 % SDS-
PAGE gels and proteins
 
were subsequently separated. After washing with distilled water,
 
the 
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gels were negatively stained with copper stain buffer (Bio-Rad).
 
The corresponding 32 kDa 
ORF2 protein band was excised
 
and the copper stain was removed using the destain buffer 
(Bio-Rad).
 
The destained gel slices containing ORF2 protein were subjected
 
to electroelution 
using a commercial apparatus (Bio-Rad). Eluted
 
proteins were collected and the 
concentration was determined
 
using a Protein assay kit (Bio-Rad). The purity of eluted 
proteins
 
was confirmed by SDS-PAGE with Coomassie brilliant blue R-250
 
(Bio-Rad). The 
purified ORF2 proteins were used in the ELISA.
 
 
Swine and chicken convalescent serum samples. Swine convalescent serum 
samples were collected from pigs experimentally
 
infected with swine HEV and human HEV 
as described previously
 
(Halbur et al., 2001). Chicken convalescent serum samples were
 
collected from chickens experimentally infected with avian HEV
 
(Sun et al., 2004b). The 
experimental swine and chicken serum
 
samples used in this study were collected at 28 and 
42 days
 
post-infection, respectively. A panel of positive and negative
 
swine serum samples 
from naturally infected pigs from different
 
countries (Meng et al., 1999b) was also used in 
this study.
 
 
Peptide synthesis and production of rabbit antisera. Nine truncated peptides were 
commercially synthesized and purified
 
(SynPep). The amino acid sequences of the peptides 
and their
 
locations on avian HEV ORF2 protein are shown in Fig. 1.
 
Peptides 1, 2, 3 and 4 
include the full-length of domains I,
 
II, III and IV, respectively. Peptides 5 and 6 contain the 
second
 
and first half of domain I, respectively; peptides 7 and 8 consist
 
of the first and second 
half of domain II, respectively; and
 
peptide 9 has four more amino acid residues than peptide 
8 at
 
the N terminus. All peptides were conjugated with keyhole lympet
 
haemocyanin (KLH) 
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and each peptide-KLH was emulsified with an
 
equal volume of Freund's complete adjuvant. 
Each peptide (100 µg
 
per rabbit) was used to immunize two New Zealand white rabbits.
 
The 
initial immunization was given on day 0 by intramuscular
 
injection. A booster injection with 
peptide-KLH in Freund's
 
incomplete adjuvant was given 14 days later. Blood was
 
collected 
before each injection and 14 days after the booster.
 
 
Detection of rabbit anti-peptide antibodies. Two rabbit sera from each peptide-
immunized group were tested
 
immediately after each bleed and pooled. The pooled sera from
 
two rabbits against peptide 1 through to peptide 9 were designated
 
RS1–RS9 and used 
throughout this study. Each of the pooled
 
rabbit sera was tested by an ELISA against each of 
the nine
 
peptides as well as avian HEV ORF2 protein, human HEV (Sar-55
 
strain) 
recombinant ORF2 protein (Robinson et al., 1998) and
 
swine HEV recombinant ORF2 
protein (Meng et al., 2002). ELISA
 
plates (Nunc) were coated with peptides or ORF2 
antigens at
 
100 ng per well overnight at 4 °C. After washing with
 
PBS/T [0·01 M PBS, 
pH 7·2, containing
 
0·05 % Tween 20 (v/v)], the wells were blocked with 3
 
% BSA (w/v) in 
PBS/T for 60 min at room temperature. Rabbit
 
sera at various dilutions in PBS/T were added 
in duplicate and
 
incubated for 60 min at room temperature. Goat anti-rabbit
 
immunoglobulin 
G (IgG) (H+L)-HRP conjugate (Jackson ImmunResearch)
 
(diluted 1/1000 in PBS/T, 100 µl 
per well) was added
 
to each well. After incubating for 60 min and a final washing
 
step, the 
substrate (O-phenylenediamine dihydrochloride; Sigma-Aldrich)
 
was added for colour 
development. After 15 min the reaction
 
was stopped by adding 3 M H2SO4 to each well 
(50 µl
 
per well), and read at A490 on an automatic ELISA plate reader
 
(Universal Microplate 
Reader, EL800; Bio-Tek Instrument).
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Detection of swine or chicken antibodies against ORF2 antigen and peptides. 
Swine or chicken anti-HEV antibodies were detected using ELISA
 
as described above except 
that the sera were diluted 1/100 in
 
PBS/T, goat anti-swine IgG (H+L) and goat anti-chicken 
IgY-HRP
 
conjugate (Jackson ImmunResearch) were used as the secondary
 
antibodies.
 
 
Statistical analysis. Statistical analysis was performed using t-test (Microsoft Excel
 
2003) to compare the differences in ELISA absorbance values
 
between pre-immune and 
immune rabbit sera reacting with ORF2
 
antigens. P values of ≤ 0·05 were considered 
significant. 
Results 
Expression and purification of avian HEV ORF2 protein  
As expected, the avian HEV ORF2 protein was expressed as an
 
inclusion body in 
bacterial cells with a high yield (Fig. 2a
 
and b). Further purification of the ORF2 protein was 
performed
 
by electroelution. From 9 mg of inclusion body effluent
 
proteins, which originated 
from 100 ml of bacterial culture,
 
we obtained approximately 5·4 mg of purified ORF2
 
proteins, as demonstrated in the SDS-PAGE gel (Fig. 2c). 
Titration of rabbit antisera 
Titration of rabbit anti-peptide antisera (RS1–RS9) was
 
performed by ELISA. Serum 
titres were defined as the highest
 
serum dilution that gave an A490 of 1·0. RS2–RS7
 
had titres 
between 10
3
 and 10
4
 as shown in Fig. 3, and
 
RS1, RS8 and RS9 had titres between 10
4
 and 
10
5
. The titres
 
of pre-immune rabbit sera were <10
2
 (data not shown). 
Cross-reactivity of rabbit antisera with nine synthetic peptides  
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To determine the cross-reactivity of rabbit antisera against
 
the nine peptides, RS1–
RS9 were tested against individual
 
peptides in the ELISA. Three peptides (peptides 1, 5 and 
6)
 
were generated from domain I. As shown in Fig. 4, RS1 reacted
 
with peptides 1 and 5 (A490 
1·280 and 1·111, respectively)
 
and RS5 reacted with peptides 5 and 1 (A490 0·810 and
 
1·213, 
respectively). RS1 and RS5 did not cross-react
 
with peptide 6. RS6 reacted only with peptide 
6 but not with
 
peptides 1 and 5. These data suggested that the B-cell epitope(s)
 
of domain I 
was located in the second half of the domain (aa
 
400–410). 
For domain II, four peptides (peptides 2, 7, 8 and 9) were produced
 
and used to 
immunize rabbits. RS2 reacted with peptides 2 (A490
 
1·136), 8 (A490 1·026) and 9 (A490 1·239)
 
but not with peptide 7 (A490 0·062). RS8 and RS9 cross-reacted
 
with peptide 2 (A490 0·631 
and 0·617, respectively)
 
and to each other (A490 1·020 and 1·185, respectively).
 
In contrast, 
RS7 only reacted with peptide 7 (A490 0·964)
 
and did not react with peptide 2 (A490 0·130). 
These
 
results suggest that one or more B-cell epitopes are located
 
in the second half of 
domain II (aa 477–492) and that
 
the N-terminal 4 aa extension in peptide 9 is an important
 
part of the epitope. As expected, there was no cross-reaction
 
among peptides 1, 2, 3 and 4. 
Cross-reactivity of rabbit antisera against ORF2 proteins of avian, swine and human 
HEVs  
To determine whether rabbit anti-peptide sera can recognize
 
ORF2 proteins, RS1–
RS9 were tested for their reactivity
 
with avian, swine and human HEV recombinant ORF2 
antigens by
 
ELISA. As shown in Fig. 5, in comparison with pre-immune
 
sera, RS1, RS4, RS8 
and RS9 reacted with avian HEV ORF2 (P values
 
of 0·02, 0·004, 0·02 and 0·01, 
respectively).
 
RS1 along with RS4 and RS6 also reacted with human HEV ORF2
 
(P value of 
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0·002, 0·02 and 0·01, respectively).
 
Only RS1 reacted with swine HEV ORF2 (P value of 
0·02).
 
Thus, RS1 reacted with all three recombinant ORF2 antigens.
 
 
A panel of swine serum samples from pigs naturally infected
 
with swine HEV (Meng 
et al., 1999b) was also used to evaluate
 
the cross-reactivity with avian HEV ORF2 antigens. 
Three swine
 
HEV antibody-positive pig sera from Canada reacted with avian
 
HEV ORF2 
antigen, but only one reacted with peptide 1 (Table 1),
 
whereas three negative sera did not 
react with these antigens.
 
Similar results were also obtained from swine HEV-positive pig
 
sera from Korea, Thailand and the USA except that one pig from
 
Korea and one from 
Thailand reacted with peptide 4 in addition
 
to avian HEV ORF2 antigen and peptide 1. The 
third pig serum
 
from Thailand reacted with avian HEV ORF2 antigen and peptide
 
1. Three 
pig sera from China reacted with avian HEV ORF2 antigen
 
and peptides 1–4, suggesting that 
these pigs were infected
 
with avian HEV, since pigs and chickens are reared together
 
in many 
backyard farms in China. This may indicate the possibility
 
of transmission of avian HEV 
from chicken to pigs. This possibility
 
was further supported by the fact that pigs can be 
experimentally
 
infected with avian HEV as reported by Kasorndorkbua et al.
 
(2005).
 
 
As positive and negative controls, serum samples from six chickens
 
experimentally 
infected with avian HEV and four chickens negative
 
for avian HEV were tested against these 
antigens. Convalescent
 
serum samples collected at 42 days post-inoculation strongly
 
reacted 
with avian HEV ORF2 antigen and peptide 1, 4 and 8 (Table 1)
 
but not with peptides 2 and 3. 
Collectively, these data indicate
 
that the B-cell epitopes present in the antigenic domain I are
 
common to avian, human and swine HEV ORF2 proteins. A B-cell
 
epitope in domain II 
might be unique to avian HEV. Although
 
the B-cell epitopes in domain IV are shared 
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between avian and
 
human HEVs, the fact that pig sera from swine HEV naturally
 
infected 
pigs collected from China, Korea and Thailand suggests
 
the possible transmission of avian 
HEV to pigs.
 
 
Discussion 
Avian HEV is an emerging virus that is enzootic in chicken flocks
 
in the USA. 
Current ELISA methods using the recombinant ORF2
 
protein for serological diagnosis cannot 
differentiate avian
 
HEV from human and swine HEV infections due to the cross-reactivity
 
between the ORF2 capsid antigens (Haqshenas et al., 2001). Based
 
on the four predicted 
major antigenic domains in avian HEV ORF2
 
capsid protein (Fig. 1), we synthesized nine 
peptides and
 
produced rabbit antisera against them (Fig. 2) to identify
 
epitopes that are 
specific for avian HEV and that are common
 
to human and swine HEVs.
 
 
Cross-reactivity studies using the rabbit antisera against the
 
nine peptides revealed 
that a B-cell epitope is located in the
 
second half of domain I since RS1 (against peptide 1, 
entire
 
domain I between aa 389 and 410) and RS5 (against peptide 5,
 
between aa 399 and 
410) cross-reacted with each other (Fig. 4).
 
We speculate that there may be a B-cell epitope in 
domain I
 
between aa 399 and 410, since RS6 (against peptide 6, aa 389–398)
 
did not cross-
react with peptide 1, and peptide 5 is only 12 aa
 
long. However, cross-reactivity studies 
between rabbit antisera
 
and recombinant ORF2 proteins suggested that additional epitopes
 
may exist in domain I that are common among avian, human and
 
swine HEV ORF2 proteins, 
since RS1 reacted with all three ORF2
 
proteins (Fig. 5). The facts that RS1 reacted more 
strongly
 
with human (A490 >3·0) and swine HEV ORF2 proteins
 
(A490 1·5) than with avian 
HEV ORF2 protein (A490 0·82),
 
and that RS5 did not react with any ORF2 proteins and RS6 
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reacted
 
only with human HEV ORF2 suggest that these epitopes in domain
 
I may be 
conformational and presented differently among these
 
three ORF2 proteins, and thus may be 
influenced by amino acid
 
residues outside these domains. This was further supported by
 
the 
fact that, despite a 98 % amino acid sequence identity between
 
human ORF2 (Sar-55) and 
swine ORF2 (Meng et al., 1999b), RS6
 
only reacted with human HEV ORF2 and not with 
swine HEV ORF2
 
proteins.
 
 
Domain II is the longest of the four predicted antigenic domains,
 
with 32 aa (aa 461–
492); therefore, four peptides
 
were synthesized with 32, 16, 16 and 20 aa, corresponding
 
to 
peptides 2, 7, 8 and 9, respectively (Fig. 1). Rabbit
 
antisera of RS2, RS8 and RS9 cross-
reacted with each of the
 
others, indicating that one or more B-cell epitopes on avian
 
HEV 
ORF2 are located between aa 473 and 492 at the C terminus.
 
Since RS8 and RS9 only reacted 
with avian HEV ORF2 (Fig. 5)
 
and since they cross-reacted equally well with each other and
 
with peptide 2 (Fig. 4), the epitope on the antigenic domain
 
II is likely to be located between 
aa 477 and 492 and expressed
 
only on avian HEV ORF2 protein (Fig. 4). The fact that
 
RS2 
did not react with avian HEV ORF2 suggested that the N-terminal
 
amino acid residues may 
block the C-terminal epitope presentation,
 
since peptides 8 and 9 are truncated from the C 
terminus of
 
peptide 2 (Fig. 1). This result is consistent with the
 
findings by Riddell et al. 
(2000) in which the monoclonal antibodies
 
did not recognize human HEV ORF2 antigen 
within this region,
 
indicating that other domains are involved in the antigenicity
 
of domain II.
 
 
Antigenic cross-reactivity studies using antisera from pigs
 
naturally infected with 
swine HEV and experimentally infected
 
with swine and human HEVs (Table 1) support the 
hypothesis
 
that avian HEV ORF2 domain I contains at least one epitope that
 
is common 
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among avian, human and swine HEVs and domain IV contains
 
epitope(s) shared between 
avian and human HEVs. The epitopes
 
in domain IV that are shared between avian and human 
HEVs are
 
likely to be located at the C terminus of ORF2 (Schofield et
 
al., 2003), despite the 
sequence differences between these proteins
 
(Fig. 1). In contrast, peptide 2 contains a B-cell 
epitope
 
only presented on avian HEV ORF2, as demonstrated by the fact
 
that RS8 and RS9 
rabbit antisera reacted with avian HEV ORF2
 
(Fig. 5) and that convalescent antisera from 
chickens experimentally
 
infected with avian HEV also reacted with peptide 8 (Table 1).
 
Interestingly, convalescent chicken antisera did not react with
 
peptide 2 but did react with 
peptide 8, suggesting that the
 
epitope in peptide 8 was not accessible on peptide 2 when it
 
was 
used in ELISA.
 
 
In summary, we found that domains I and IV contained epitopes
 
in ORF2 protein that 
are shared among three strains of HEV,
 
supporting further the classification of avian HEV in 
the genus
 
Hepevirus of the family Hepeviridae (Emerson et al., 2004).
 
ORF2 protein from 
either avian, human or swine HEV can be used
 
to detect anti-HEV antibodies. The ORF2 
proteins from human
 
and swine HEVs have been shown to be equally efficient as diagnostic
 
reagents for the detection of anti-HEV antibodies (Engle et
 
al., 2002). In this study, we found 
that peptide 4, corresponding
 
to antigenic domain IV, is useful for the detection of avian
 
and 
human HEVs and that peptide 8 can be used for the detection
 
of anti-avian HEV antibodies. 
Currently, we do not know if these
 
epitopes are neutralizing epitopes. Future studies of the 
immunogencity
 
of peptides 1, 4 and 8 along with avian HEV ORF2 protein in
 
chickens and 
their ability to protect against avian HEV infection
 
are warranted.
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Table 1. Antigenic cross-reactivity of convalescent antisera from pigs experimentally 
infected with swine and human HEVs, from pigs naturally infected with swine HEV and 
from chickens experimentally infected with avian HEV with truncated ORF2 protein and five 
synthetic peptides of avian HEV. Indirect ELISA was used to detect swine and chicken sera 
against ORF2 and peptides. The sera were diluted at 1/100 and the ORF2 and peptides were 
used at 100 ng per well. 
 
 
*
 The numbers are the mean ELISA absorbance values ± standard deviation. 
† 
The values in bold are considered positives. 
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Figure 1. Amino acid sequence and locations of 9 synthesized peptides in avian HEV ORF2 
protein (Haqshenas, et al., 2002). (a) Peptides 1, 2, 3, 4 are the full antigenic domain I, II, III, 
IV, respectively; peptides 5 and 6 are truncated from peptide 1; peptides 7, 8, 9 are derived 
from peptide 2. (b) Amino acid sequences in the four antigenic domains were compared to 
the corresponding region of swine HEV and human HEV (Sar-55 strain).  Dots represent 
residues identical to those in avian HEV. Dashes represent amino acid residues deletions in 
swine and human HEV. 
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Figure 2. Expression and purification of avian HEV ORF2 protein. (a) Lanes 1-2, SDS-
PAGE analysis of two bacterial cell clone lysates at 4 hours after IPTG induction. (b) Lanes 
1-3, SDS-PAGE analysis of three continuous effluent fractions from inclusion body 
purification with His-Bind resin column. (c) Lane 1, SDS-PAGE analysis of inclusion body 
proteins after electric elution purification.  The expected size of the truncated avian HEV 
ORF2 proteins product is 32kDa. 
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Figure 3. Titration of rabbit anti-sera (RS1–9). Each point represents the mean absorbance 
values obtained from RS1–9 performed in duplicates. The absorbance value of 1·0 was used 
as the end-point titre. 
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Figure 4. Cross-reaction of rabbit anti-sera (RS1-9) with nine peptides.  Rabbit sera were 
diluted at 1/1000 and used in the ELISA against peptides 1-9 (from left to right in each panel 
column).  Each bar represents the mean absorbance values obtained from RS1-9 performed in 
duplicates ± standard error.  
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Figure 5. Reaction of rabbit anti-sera (RS1–9) with avian HEV ORF2 (black), human HEV 
ORF2 (grey) and swine HEV sORF2 (hatched) antigens. Open bars, pre-immune sera. Each 
bar represents the mean absorbance values obtained from RS1–9 performed in duplicates ± 
standard error. All sera were diluted at 1/1000. *, Statistical significance compared with the 
pre-immune sera (P ≤ 0·05).  
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CHAPTER 4. PROTECTION OF CHICKENS AGAINST AVIAN HEPATITIS E 
VIRUS (AVIAN HEV) INFECCTION BY IMMUNIZATION WITH RECOMBINANT 
AVIAN HEV CAPSID PROTEIN 
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Abstract  
Avian hepatitis E virus (avian HEV) is an emerging virus associated with hepatitis-
splenomegaly syndrome in chickens in North America. Avian HEV is genetically and 
antigenically related to human HEV, the causative agent of hepatitis E in humans. In the lack 
of a practical animal model, avian HEV infection in chickens has been used as a model to 
study human HEV replication and pathogenesis. A 32 kDa recombinant ORF2 capsid protein 
of avian HEV expressed in E. Coli was found having similar antigenic structure as that of 
human HEV containing major neutralizing epitopes. To determine if the capsid protein of 
avian HEV can be used as a vaccine, twenty chickens were immunized with purified avian 
HEV recombinant protein with aluminum as adjuvant, and another twenty chickens were 
mock immunized with KLH precipitated in aluminum as controls. Both groups of chickens 
were subsequently challenged with avian HEV. All the tested mock-immunized control 
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chickens developed typical avian HEV infection characterized by viremia, fecal virus 
shedding and seroconversion to avian HEV. Gross hepatic lesions were also found in portion 
of these chickens. In contrast, none of the tested chickens immunized with avian HEV capsid 
protein had detectable viremia, fecal virus shedding or observable gross hepatitis lesions. The 
results from this study suggested that immunization of chickens with avian HEV recombinant 
ORF2 capsid protein with aluminum as adjuvant can induce protective immunity against 
avian HEV infection. Chickens are a useful small animal model to study anti-HEV immunity 
and pathogenesis.  
Key words: Avian hepatitis E virus; ORF2 capsid protein; Immunization.  
Abbreviated article title: Protection of chickens against avian HEV infection.  
Introduction 
Avian hepatitis E virus (HEV) was recently isolated from chickens with hepatitis-
splenomegaly syndrome (HS) syndrome in the United States [1] and proved to be the primary 
causative agent of HS syndrome [2], an emerging chicken disease in North America [1,3,4].  
Avian HEV is a member of the genus Hepevirus, which also includes human and swine 
hepatitis E viruses [5]. Phylogenetic analysis revealed that avian HEV represents a branch 
distinct from human and swine HEVs, and probably represents a 5th genotype [6]. The 
genome of mammalian HEVs is approximately 7.2 kb in size and contains three partially 
overlapping open reading frames: ORF1, ORF2, and ORF3 [7] which encode, respectively, 
for nonstructural proteins,
 
putative capsid protein, and a
 
small protein that may be involved in 
HEV structural assembly and virus-host interaction [8–10]. The genomic organization of 
avian HEV is similar to that of mammalian HEVs, although avian HEV is approximately 600 
 77  
 
bp shorter than mammalian HEVs because of the majority of the deletions in the 
hypervariable region of avian HEV ORF1 [6].   
Humoral immune responses play an important role in anti-HEV immunity, and are 
mostly induced by the ORF2 capsid protein [11–15]. Several studies have demonstrated that 
the ORF2 capsid protein can induce efficient neutralizing antibodies to prevent HEV 
infection [16–20].  Rhesus monkeys immunized with truncated human HEV ORF2 protein 
expressed in insect cells can avoid HEV infection and development of hepatitis [21–24].  The 
human HEV recombinant ORF2 protein containing the major neutralizing epitopoes is 
currently used as a vaccine in a field trial in Nepal [25].  Immunization with recombinant 
HEV ORF2 protein can protect monkeys not only from homologous virus challenge but 
heterologous challenges as well [20, 26,27 and 28].  Human HEV ORF2 proteins expressed 
in bacteria were equally efficient in eliciting protective immunity against HEV infection 
[29,30].  Human HEV ORF2 DNA vaccines also induced protective anti-ORF2 antibody 
responses [31–33].    
We reported the expression of the C-terminal 268 residues of avian HEV ORF2 
protein in bacterial cells and demonstrated that it contains similar antigenic domains to the 
corresponding region of human and swine HEVs and shares common antigenic epitopes with 
that of human and swine HEVs, although avian HEV capsid protein is approximately 60 
amino acids shorter than the mammalian HEV counterparts [6,34]. Two B cell epitopes 
common to both avian HEV and human HEV were recently identified on the avian HEV 
capsid protein [35].  In this study, we further demonstrated that the recombinant ORF2 
protein of avian HEV can provide protective immunity against avian HEV infection in 
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chickens.   
Materials and Methods  
2.1. Avian HEV virus  
Since avian HEV can not be propagated in vitro [36], an avian HEV infectious stock 
was produced by intravenously inoculating chickens with 200 µl of the avian HEV fecal 
suspensions with a titer of 10
3
 50% chicken infectious doses
 
(CID50) per ml [36].  The 
generated avian HEV stock containing 1×10
4
 genome equivalent (GE)/ml or 500 CID50 /ml 
of avian HEV in 10% feces suspension was used for infecting chickens. 
2.2. Specific-pathogen-free (SPF) chickens 
Forty 15-week-old SPF chickens purchased from M&C Anderson Pullets (Sioux 
Rapids, IA) and tested negative for anti-avian HEV ORF2 antibody were divided into two 
groups of 20 each and housed in two separated rooms.  Group 1 chickens (ID #25 – #44), 
four chickens per cage, were each immunized with avian HEV ORF2 protein, and group 2 
chickens (ID #5 – #24), four chickens per cage, were mock immunized as controls. 
2.3. Immunization of chickens with avian HEV ORF2 protein 
The recombinant pRSET-C plasmid containing the truncated ORF2 gene of avian 
HEV was constructed as described previously [34].  The expression and purification of the 
truncated avian HEV ORF2 protein were described elsewhere [35,36].  The purified avian 
HEV ORF2 protein was coupled to Keyhole Limpet Hemocyanin (KLH) (Pierce, Rockford, 
IL) and precipitated in aluminum according to the protocol established previously [37].  
Chickens in group 1 were each immunized intramuscularly with 200 µg of purified avian 
HEV ORF2 protein at two sides of the breast, and boosted twice at two weeks intervals.  
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Chickens in group 2 were each similarly given equal amounts of KLH precipitated in 
aluminum.  Blood was collected from all chickens prior to immunization, and weekly after 
immunization from each chicken.  
2.4. Virus challenge and sample collection 
Two weeks after the second booster immunization, all chickens were challenged
 
intravenously with 100 µl of the avian HEV infectious stock containing 1000 GE or 50 CID50 
virus dose. Serum and fecal samples were collected weekly from each chicken and used for 
detection of viremia and the presence of avian HEV RNA.  Fecal virus shedding and viremia 
were monitored for 5 weeks.  Four chickens from each group were necropsied at one, two, 
four weeks post-challenge (WPC), respectively, and the remaining chickens were necropsied 
at five WPC.  During each necropsy, bile samples were collected from each chicken and gross 
liver pathological changes were recorded by digital camera.  
2.5. Detection of avian HEV by RT-PCR 
To detect avian HEV RNA by RT-PCR, the viral RNA was extracted from 100 µl of 
fecal, serum or bile samples with with RNAgents® Total RNA Isolation System (Promega).  
Total RNA was resuspended
 
in 10 µl of DNase-free, RNase-free and proteinase-free
 
water 
(MP Biomedicals, CA).  Reverse transcription (RT) was performed
 
at 42 °C for 60 min in the 
presence of a master mixture consisting
 
of 10 µl of total RNA, 0.25 µl of AMV reverse 
transcriptase (Promega), 1 µl of 10 µM
 
antisense primer, 0.5 µl of RNase inhibitor, 4 µl of 5 
× RT buffer, and 1 µl
 
of 10 mM dNTP.  
The resulting cDNA was
 
amplified by a nested RT-PCR with Taq DNA polymerase
 
(Promega) and two pairs of primers as described previously [36] with the following 
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modifications.  For the first round PCR, the reactions were incubated at 95 °C for 5 min, 
followed by 38 cycles of amplification at 94 °C for
 
1 min for denaturation, 1 min at 52 °C for 
annealing, and 1 min at 72 °C for extension, with a final incubation
 
period at 72 °C for 7 min.  
For the second round PCR, 5 µl of the first PCR products were used as the templates. The 
parameters were the same as the first round PCR with the exception of 53 °C annealing 
temperature and 35 amplification cycles.  PCR was performed using the Mastercycler 
Personal (Eppendorf, NY) thermocycler.  The final PCR products were examined
 
on a 1.2% 
agarose gel containing with 1.0 µg/ml ethidium bromide.   
2.6. Sequencing and sequence analysis 
Two positive fecal samples were selected and amplified by RT-PCR using the high-
fidelity ProofStart DNA polymerase (Qiagen, CA). The final PCR products of 221bp were 
sequenced for both strands using ABI 3730 DNA Analyzer (Applied Biosystems, CA) at Iowa 
State University DNA Facility (Ames, Iowa) to confirm the identity of the viruses
 
recovered 
from the infected chickens. Sequences were aligned and analyzed using the MegaAlign 
program (DNA STAR Inc., Madison, WI). 
2.7. ELISA assay 
Chicken serum samples collected 2 weeks after 2nd and 3rd immunization and 
weekly after virus challenge were titrated by ELISA to determine the anti-avian HEV ORF2 
antibody levels.  Briefly, 96-well flat bottom plates (Nunc
TM
, USA) were coated with avian 
HEV ORF2 proteins (100 ng/well) overnight at 4
o
C.  Each well of the plate was blocked with 
200 µl of 2.5% non-fat dry milk in PBS containing 0.05% Tween-20 (PBS’T) for 1 hour at 
room temperature.  After washing with PBS’T, chicken sera diluted in 2.5% non-fat dry milk 
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PBS’T were added to the plate in duplicates and incubated for 1 hour at room temperature.  
Goat anti-chicken IgY Fc fragment-HRP conjugate (Bethyl Laboratories Inc., Texas) (1:2000 
diluted in PBS'T, 100 µl/well) were added to each well and incubated for 1 hour.  After a final 
washing step, 100 µl of o-Phenylenediamine Dihydrochloride substrate (Sigma) was added to 
develop colorimetric reaction for 15 min.  The reaction was then stopped by adding 3M 
H2SO4 in each well (50 µl/well) and read at 490 nm on an automatic ELISA plate reader 
(Universal Microplate Reader, EL800, Bio-Tek Instrument, Inc., Winooski, VT).   
To differentiate antibodies produced in response to immunization of avian HEV 
ORF2 protein from those against avian HEV infection, a peptide (named peptide 10) was 
synthesized and purified at Iowa State University Protein Facility and used as the differential 
antigen.  Peptide 10 is located at N terminal antigenic domain V with the amino acid 
sequence of GRRGQRRRDNSAQWSTQQRPEGAV. The antigenic profiles on full-length 
avian HEV ORF2 (Fig. 3) showed that the antigenic domain V does not overlap with the C- 
terminal truncated avian HEV ORF2 protein used as the immunogen in this study.  The 
differential ELISA was performed essentially as described previously [35], except that 200 ng 
of peptide 10 was coated in each well and sera were 1:100 diluted.  Anti-avian HEV positive 
and negative chicken sera were used as controls.  
2.8. Detection of serum lactate dehydrogenase (LDH) 
It has been demonstrated that avian HEV infection results in the elevation of chicken 
serum LDH [2].  Cytotoxicity LDH detection kit (Roche Applied Science, IN) was used to 
measure the LDH levels in the chicken sera collected after virus challenge according to the 
manufacture’s instruction.  Briefly, chicken sera were 1:10 diluted with freshly prepared 1% 
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bovine serum albumin (BSA) in 100mM PBS (pH 7.5).  Chicken LDH standard (Sigma) was 
also serially diluted and used to establish a standard curve.  Freshly mixed catalyst and dye 
solution (100 µl) provided in the kit were added into each well of 96-well ELISA plate, 
followed by adding 100 µl of diluted serum samples and chicken LDH in duplicates.  The 1% 
BSA diluent was added and used as a background control.  After incubation at room 
temperature for 20 min, the reaction was stopped by adding 1N HCl (50 µl/well) and 
measured with ELISA reader at 490 nm.  The absolute LDH activity in chicken sera was 
inferred from the LDH standard curve. 
2.9. Statistical analysis 
Statistical analysis was performed as described previously [35]. P values of ≤0.05 
were considered significant. 
Results 
3.1. Anti-avian HEV ORF2 response to immunization with recombinant ORF2 antigen 
To generate a background binding value for the chicken serum samples, ELISA plates 
coated with avian HEV ORF2 antigen were reacted with 40 chicken serum samples negative 
for avian HEV.  The average OD value was 0.1763 with a standard deviation (STDEV) of 
0.0455.  Therefore, an OD value of 0.358, which is 4 STDEV above the mean OD value of 
negative chicken sera, was used as the ELISA cut-off value.  The anti-avian HEV ORF2 
antibody titers in response to immunization with recombinant ORF2 antigen were defined as 
the last serum dilution that gives an OD value above 0.358.  After 2nd immunization, the 
majority of the immunized chickens had a serum titer of approximately 1:10,000 (Fig. 1).  At 
1:1000 dilution, 6 chickens had OD values of >2.5, 9 chickens of 1.75-2.5 and 5 chickens of 
 83  
 
1.0-1.75.  The anti-avian HEV ORF2 antibody levels did not increase significantly in these 
chickens after the 3rd immunization (data not shown).  As expected, the chickens that were 
mocked immunized with KLH precipitated in aluminum did not develop specific anti-avian 
HEV ORF2 antibodies (average OD value was 0.13).  
3.2. Immunization of chickens with recombinant ORF2 prevents viremia and virus 
shedding in feces and bile 
Serum, fecal and bile samples from all chickens were negative for avian HEV RNA at 
0 WPC.  The samples collected from 1 to 5 WPC from avian HEV ORF2 protein immunized 
chickens were all negative for avian HEV RNA (Table 1).  In contrast, serum viral RNA was 
detected in mock-immunized chickens starting at 1 WPC and remained positive for at least 
another 4 weeks.  Fecal viral RNA was detected in 14/20, 16/16, 11/12, 11/12 and 8/8 mock-
immunized chickens at 1, 2, 3, 4 and 5 WPC, respectively.   Avian HEV RNA was detected 
from bile samples in 4/4, 3/4, 1/4 and 2/8 mock immunized chickens at 1, 2, 4 and 5 WPC, 
respectively (Table 1).  Sequencing results of the PCR products amplified from chicken #19 
and #22 confirmed the recovered viruses were originated from the inoculum. These 
sequences were deposited within GeneBank with the accession numbers of DQ111980 and 
DQ111981. 
3.3. Anti-avian HEV ORF2 responses after challenge with avian HEV 
Serum samples colleted from 16 chickens that were monitored consecutively from 1 
to 5 WPC were tested to evaluate the kinetics of anti-avian HEV ORF2 antibody responses.  
In the 8 chickens immunized with avian HEV ORF2 protein, the anti-avian HEV ORF2 
antibodies remained at high levels after the 2nd immunization but declined rapidly at 1 WPC 
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and remained at lower levels for at least another 4 weeks (Fig. 2).  A transient increase of the 
anti-avian HEV ORF2 antibody level in chicken #37 occurred between 3 and 4 WPC and 
declined thereafter.  The mock-immunized chickens were negative for anti-avian HEV ORF2 
antibodies before challenge, and seroconverted to avian HEV antibodies in response to 
challenge at 3 WPC, and the antibody levels increased steadily for at least another 2 weeks.   
3.4. Anti-peptide antibody responses after avian HEV challenge: differentiation of anti-
avian HEV antibody responses induced by immunization from virus infection 
Through the antigenic analysis of the avian HEV ORF2 protein, several potential 
antigenic domains were identified (Fig. 3) in addition to the previously identified four 
domains [34].  Domain V is most antigenic in the N terminus.  Peptide 10 is within this 
domain and was used in the ELISA to detect and differentiate anti-avian HEV antibodies 
induced by the avian HEV challenge from the antibody response induced by immunization 
with truncated ORF2 protein.  At 0 WPC (2 weeks after the third immunization) and 1 WPC, 
all 16 chickens had no detectable anti-peptide 10 antibodies (approximately 0.087 OD value) 
(Fig. 4).  Anti-peptide 10 antibodies were not detected in chickens immunized with the avian 
HEV ORF2 recombinant protein from 1 to 5 WPC except for one chicken (#37) that had 
detectable anti-peptide 10 antibodies at 3 and 4 WPC with the OD values of  0.304 and 0.287, 
respectively (P value of 0.01, 0.03, respectively).  In contrast, anti-peptide 10 antibodies were 
detected from 8 mock-immunized chickens starting at or after 2 WPC and peaked at 5 WPC 
(OD values from 0.6 to 0.9).  
3.5. Serum LDH 
It has been shown that serum LDH enzyme was increased in chickens after 
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intravenous or oronasal inoculation with avian HEV [2].  In this study, serum samples 
colleted from 16 chickens that were monitored consecutively from 1 to 5 WPC were also 
tested for LDH. The average serum LDH at 1 WPC from 8 mock-immunized chickens was 
2.85 log (U/L) which was significantly higher than avian HEV ORF2 protein immunized 
chickens (2.3 log (U/L), P value of 0.017).  There was no significant difference for the levels 
of serum LDH at other WPC between the two groups of chickens (Fig. 5).  
3.6. Gross hepatic lesions 
Moderate to severe subcapsular hemorrhages were observed in the livers of 6 of 20 
mock-immunized and subsequently challenged chickens during necropsies (Fig. 6). No liver 
lesion was observed in immunized and challenged chickens.  
Discussion 
Avian HEV infection is associated with a hepatitis disease, chicken HS syndrome.  It 
has been demonstrated that avian HEV infection in chickens served as a valuable 
homologous small animal model for studying human HEV pathogenesis [2]. However, there 
is no report whether chickens can be used as model to study anti-HEV immune responses.  
Human HEV shares common antigenic epitopes in the ORF2 protein with avian HEV [34] 
and two common B cell epitopes were recently identified [35].  In this study, we 
demonstrated that chickens immunized with avian HEV ORF2 recombinant protein induced 
anti-ORF2 antibodies, and were protected from avian HEV infection and the development of 
hepatitis after challenge with avian HEV.  
 Previous studies showed that immunization with human HEV ORF2 protein 
expressed in SF9 cells protected monkeys against human HEV infection [21–24].  Recently, 
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human HEV ORF2 proteins have been expressed in bacteria and were found predominantly 
in a dimmer form [29,30].  Monkeys vaccinated with these proteins were completely 
protected against infection with a low dose virus, and partially protected with a high dose 
virus challenge [29,30].  Our results showed that a truncated avian HEV ORF2 recombinant 
protein in the monomer form expressed in bacteria [34,35] was highly immunogenic in 
chickens.  Sixteen of 20 immunized chickens developed anti-avian HEV ORF2 antibodies 
with titer of approximately 1:10,000 after 2nd immunization (Fig. 1), although the antibody 
levels varied among chickens.  The protective immunity in chickens immunized with avian 
HEV ORF2 protein was likely due to the induction of neutralizing antibodies against avian 
HEV ORF2 protein, which eliminates the challenge virus.  
Anti-avian HEV ORF2 antibody levels in 8 chickens immunized with avian HEV 
ORF2 protein decreased dramatically at 1 WPC (Fig. 2), and this observation was confirmed 
by repeated testing of the samples. Although the reason for the rapid decrease of anti-avian 
HEV ORF2 antibodies after virus challenge is not known, we believe that the anti-avian HEV 
ORF2 antibodies induced by immunization were likely processed and degraded during the 
virus neutralization process against the challenge virus.  It is known that the ingestion and 
degradation of antibody-virus complex by macrophages or natural killer cells contribute to 
the final clearance of circulating virus [38].  However, it cannot be ruled out that anti-avian 
HEV ORF2 antibodies were rapidly digested, which has been seen in other virus systems 
[39,40].  
The transient increase of anti-avian HEV ORF2 antibodies in chickens #37 after avian 
HEV challenge suggested that some viruses may escape neutralization, and consequently 
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anti-avian HEV antibodies were induced as confirmed by the detection of anti-peptide 10 
antibodies in this chicken (Fig. 4).  As avian HEV RNA was not detected in serum, fecal or 
bile samples from this chicken, the replication level of the escaped viruses was limited.  The 
reason for failing to completely neutralizing the challenge viruses in chicken #37 may be due 
to the lower level of neutralizing antibodies in this chicken as indicated by the relative low 
level of anti-avian HEV ORF2 antibodies induced by immunization (Figs. 1 and 2).  Further 
study is warrant to examine the level of neutralizing antibodies in these chickens by in vitro 
neutralizing study using the purified chicken IgY.   
Moderate to severe subcapsular lesions in the liver were observed in 6 of 20 mock-
immunized chickens, and the mean serum LDH level was also transiently increased in these 
chickens (Figs. 5 and 6).  The finding that only a portion of infected chickens developed 
gross liver pathological lesions was consistent with a previous report by Billam et al [2].  
Chickens immunized with avian HEV ORF2 immunized and subsequently challenged with 
avian HEV did not have any observable gross liver lesions or increased serum LDH after 
virus challenge, indicating that immunization of chickens with avian HEV ORF2 
recombinant protein prevented hepatitis caused by avian HEV infection.  
The dominant neutralizing epitopes on the capsid protein of human HEV were located 
in the C-terminal regions of the ORF2 [16–19].  Our study also suggested that neutralizing 
epitopes of avian HEV are located on the C terminus of the ORF2 protein, since the 
recombinant ORF2 protein of avian HEV used in the study was the C-terminal part (aa 339–
606) of the avian HEV ORF2 protein [35].  By using monoclonal antibody and series of 
recombinant avian HEV ORF2 proteins, two different neutralization epitopes (aa 138–175 
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and aa 175–232) were identified (our unpublished results), further indicating that the 
protective immunity of avian ORF2 protein was directly related to the induction of 
neutralization antibodies. 
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Table 1. Detection of avian HEV RNA in sera, fecal swabs and bile samples from chickens 
challenged with avian HEV virus. 
No. of positive sera (fecal swabs) / total no. tested at indicated WPC 
No. of positive bile samples / total no. tested at indicated WPC Chicken Group 
0 1 2 3 4 5 
Group 1
a
 
0(0)/20 
ND
c
 
0(0)/20 
0/4 
0(0)/16 
0/4 
0(0)/12 
ND 
0(0)/12 
0/4 
0(0)/8 
0/8 
Group 2
b
 
0(0)/20 
ND 
20(14)/20 
4/4 
16(16)/16 
3/4 
12(11)/12 
ND 
12(11)/12 
1/4 
8(8)/8 
2/8 
 
a: chickens were immunized with avian HEV ORF2 recombinant protein. 
b: chickens were mock immunized. 
c: not done. 
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Figure Legends 
Fig. 1. Anti-avian HEV ORF2 antibody titration in chickens immunized with the 
recombinant avian HEV ORF2 protein. Serum samples collected from 20 chickens at 2 
weeks after 2nd immunization with the recombinant avian HEV ORF2 protein were titrated 
for level of anti-avian HEV ORF2 antibodies.  Avian HEV ORF2 protein was used as the 
antigen at 100 ng/ml on the solid phase of ELISA plates.  Each point represents the mean 
values (±S.E.M.) of the OD 490 nm obtained from the 20 chickens.   
Fig. 2. Kinetics of anti-avian HEV ORF2 antibody responses in immunized chickens 
before and after challenge with avian HEV. Sera from 16 chickens were diluted at 1:1000 
and tested for the presence of anti-avian HEV ORF2 antibodies by ELISA.  Each bar 
represents the mean value (±S.E.M.) of OD 490 nm obtained from 16 chickens. Chickens # 
17 to #24 were mock immunized. Chickens # 37 to #44 were immunized with the 
recombinant avian HEV ORF2 protein. 
Fig. 3. Hydrophilicity, antigenicity and surface probability plots of the full-length avian 
HEV ORF2 protein. Antigen profiles on the full-length avian HEV ORF2 protein were 
analyzed by the Protean program (DNA STAR Inc., Madison, WI). Shaded area indicates the 
C-terminal 268 aa residues of avian HEV ORF2 protein containing 4 predicted putative 
antigenic domains [34]. Antigenic domain V was identified as the most antigenic domain 
through the combination of hydrophilicity, antigenicity and surface probability of the amino 
acids (dot boxed area).  Peptide 10 was truncated from this domain.  Sequence of this peptide 
was given in the text.  
Fig. 4. Kinetics of anti-peptide 10 antibodies in immunized chickens after challenge with 
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avian HEV. Serum samples (diluted 1:100) from 16 chickens were tested for the presence of 
anti-peptide 10 antibodies.  Each point represents the mean values (±S.E.M.) of OD 490 nm 
obtained from 16 chickens.  Chickens #17 to #24 were mock immunized. Chickens #37 to 
#44 were immunized with the recombinant avian HEV ORF2 protein. 
Fig. 5. Serum levels of LDH in chicken sera after avian HEV challenge. The log mean 
LDH values at each WPC were generated from 8 mock-immunized and 8 avian HEV ORF2 
protein immunized chickens. *, Statistical significance (P ≤0.05). 
Fig. 6. Gross hepatic lesions in chickens challenged with avian HEV. Moderate (upper) to 
severe (lower) subcapsular liver hemorrhages (arrows) were found in 6 of 20 mock-
immunized chickens after virus challenge as indicated.  Livers with moderate gross hepatic 
lesions were observed in chickens necropsied at 1 and 2 WPC, whereas livers with severe 
lesions were seen in chickens necropsied at 4 and 5 WPC.   
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Abstract 
Avian hepatitis E virus (avian HEV), an emerging virus in chickens, is genetically and 
antigenically related to human hepatitis E virus, the causative agent of hepatitis E.  To 
identify the neutralizing epitopes on the capsid protein of avian HEV, four monoclonal 
antibodies (Mabs) with IgM isotype (7B2, 1E11, 10A2, 5G10) against the recombinant avian 
HEV capsid protein were generated. 7B2, 1E11, 10A2 blocked each other for binding to 
avian HEV ORF2 protein in a competition ELISA, whereas 5G10 did not block other Mabs, 
suggesting that 7B2, 1E11, 10A2 recognize the same or overlapping epitopes and 5G10 
recognizes a different one. The epiotpes recognized by 7B2, 1E11, 10A2 were further 
mapped between aa residues 175 and 232, and the epiotpe recognized by 5G10 was between 
aa residues 138 and 175 as deterimined by Western blot with the use of 5 avian HEV ORF2 
recombinant proteins. 1E11, 10A2 and 5G10 were shown to bind to bona fide avian HEV 
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particles in vitro, although only 5G10 reacted to viral antigens in transfected LMH chicken 
liver cells. To assess the neutralizing activities of the Mabs, avian HEV virus was mixed with 
each Mab or normal mouse IgM and incubated in vitro before inoculation into SPF chickens. 
Chickens inoculated with mixtures of avian HEV and 1E11, 10A2 or 5G10 had viremia and 
fecal virus shedding delayed at least two weeks, compared to chickens inoculated with a 
mixture of avian HEV and 7B2 or normal mouse IgM, suggesting that 1E11, 10A2 and 5G10 
can partially neutralize avian HEV.  
Running title: Two neutralization epitopes on avian HEV capsid protein. 
Introduction 
Hepatitis
 
E virus (HEV) is a single-stranded,
 
positive-sense RNA virus with an 
approximate 7.2 kb
 
genome packaged within
 
a non-enveloped capsid (9, 18).  The HEV 
genome contains three open reading frames (ORFs 1, 2 and 3), which encode, the non-
structural viral proteins, capsid protein, and a small protein
 
that may be involved in 
modulating cell signaling (9, 40), respectively. HEV infection causes frequent endemic and 
rare epidemic outbreaks of acute hepatitis E in many developing countries.  The prevalence 
of IgG HEV antibody was reported in approximately 1–20 % of the population from 
industrialized countries
 
(28, 29).  Recently, increasing numbers of cases of acute hepatitis E 
not associated with travel to endemic regions have been reported in numerous industrialized 
countries, including the United States (1, 23, 26, 34).   
The first animal strain of HEV, swine HEV was isolated from pigs in the United 
States in 1997 (24).Recently, avian HEV, was identified in the United States from chickens 
with hepatitis-splenomegaly (HS) syndrome (14). Pathological lesions characteristic of HS 
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syndrome have been reproduced in specific-pathogen-free (SPF) chickens experimentally 
infected with avian HEV (6).  Avian HEV has been classified as a putative 5
th
 genotype 
within the genus Hepevirus (11), which also includes human and swine HEVs.  Although the 
genome of avian HEV is approximately 600 bp shorter than that of swine and human HEVs 
(16), it shares 50-60% nucleotide sequence identity, common antigenic epitopes and 
significant other functional features with the mammalian HEVs (12, 13, 16).  
The anti-HEV humoral immune response is sufficient to confer protective immunity 
(7, 41). The ORF2 capsid protein is the most immunogenic and responsible for the induction 
of protective humoral immune responses (22, 31, 32, 43). As a result, currently, the ORF2 
capsid protein is the target of vaccine designs
 
and the recombinant proteins expressed either 
in Escherichia
 
coli or insect cells have been used for evaluation of vaccine efficacy
 
(10, 17, 
21, 30).  Broadly reactive anti-HEV neutralizing antibodies are induced in rhesus monkeys by 
vaccination with genotype 1 HEV recombinant capsid protein, which protected rhesus 
monkeys from challenge with viruses of the other three mammalian genotypes (30). 
Convalescent sera from animals infected with one of the four mammalian genotypes can 
neutralize all other genotypes (8).  Furthermore, a major neutralizing epitope was identified 
on the HEV Sar-55 ORF2 capsid protein (36, 37) and Mabs raised against this epitope 
neutralized two mammalian HEV genotypes (8).  
Four major antigenic domains at C terminal 268 amino acid residues of avian HEV 
capsid protein were predicted (13).  Domain I is the most conserved among avian, human and 
swine HEVs, whereas domain IV is more antigenic in avian HEV than in swine and human 
HEVs.  By using 9 synthetic peptides derived from these four antigenic domains, we 
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previously demonstrated that B cell epitopes in the antigenic domain I are shared among 
avian, human and swine HEV capsid proteins, and epitopes in domain IV are shared between 
avian and human HEVs, and one epitope in domain III is unique to avian HEV (12).  
However, our unpublished data showed that none of the rabbit antibodies raised against these 
peptides could neutralize low infectious doses of avian HEV, suggesting that the potential 
neutralizing epitopes are either located in other region(s) or they are non-lineal.  To identify 
the potential neutralizing epitopes, we first generated Mabs against avian HEV ORF2 capsid 
protein and their abilities to neutralize avian HEV were subsequently investigated in 
chickens. In addition, series of truncated avian ORF2 recombinant proteins were expressed 
and used to map the epitopes recognized by these Mabs.   
Materials and Methods 
Antigen preparation. The recombinant pRSET-C plasmid harboring the truncated 
ORF2 capsid gene of avian HEV was produced as described previously (13).  Recombinant 
avian HEV ORF2 capsid protein was expressed as inclusion body with an estimated 
molecular weight of 32 kDa and purified according to the methods described elsewhere (12).  
Ten mg of the purified protein was precipitated in aluminum as previously described (35).   
Immunization. Four BALB/c mice were injected intraperitoneally with 100µg of 
prepared avian HEV ORF2 capsid protein followed by two booster doses at two-week 
interval.  Mice were bled before each injection and two weeks after the 2
nd
 and 3
rd
 injection.   
Hybridoma production. Two weeks after the 3
rd
 immunization, mice showing 
highest antibody titers were selected as the spleen cell donors.  Four days prior to the fusion, 
the donor mice were given a final boost injection of 100 µg of the antigen.  Hybridomas were 
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produced by the fusion of spleen cells with SP2/0 murine myeloma cells by standard PEG-
mediated fusion methods.  
Indirect ELISAs. Hybridomas were screened for secreting Mabs with an indirect 
ELISA as described previously (12) with the following modifications.  Briefly, ELISA
 
plates 
were coated with avian HEV ORF2 capsid protein overnight at 4°C.  After washing and 
blocking the plates, 100µl hybridoma supernatants were added to each well in duplicates and 
incubated for 1 hr.  HRP-conjugated goat anti-mouse IgG + IgM(H+L) (Jackson 
ImmunoResearch) was added as detecting antibodies.  O-phenylenediamine dihydrochloride 
(OPD) (Sigma) was used as the substrate.  Supernatants from hybridoma cells with OD 
values of 3 times higher than that from SP2/0 cells were considered positive and the 
corresponding hybridoma cells were subjected to two more rounds of cloning and selection in 
order to establish the stability and specificity.  A total of four Mabs was obtained with the 
isotypes of IgM with a κ-light chain as determined by a mouse monoclonal antibody 
isotyping kit (Bio-Rad, CA). 
To test the specificity of Mabs, four other recombinant proteins of human HEV Sar-
55 ORF2 (33), swine HEV ORF2 (25), porcine reproductive and respiratory syndrome virus 
(PRRSV) nucleocapsid (N) and porcine circovirus (PCV) ORF2 proteins (27) and nine 
synthetic peptides truncated from avian ORF2 antigenic domains (12) were coated in ELISA 
plates at 1µg/ml overnight at 4°C.  After blocking and washing the plates, Mabs at various 
dilutions were added into each well and incubated for 1 hour.  HRP-goat anti-mouse IgM, µ 
chain specific (Jackson ImmunoResearch) was used as the secondary antibody.   
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Flow cytometry analysis. The surface IgM profiles of the hybridomas were analyzed 
by flow cytometry on a Beckton-Dickinson FACScan (Beckton-Dickinson, CA).  Hybridoma 
cells (1 x 10
6
) were stained with FITC-AffiniPure Monovalent Fab Fragment Goat Anti-
Mouse IgM, µ chain specific (Jackson ImmunoResearch) in accordance with a standard 
protocol provided by Flow Cytometry Facility at Iowa State University.  Normalized mean 
fluorescence
 
intensities (MFI) were calculated using CellQuest software (Beckton-Dickinson, 
CA).  
Competitive ELISA. The spatial relationships of epitopes recognized by each of the 
Mabs were evaluated by a pair-wise competitive ELISA essentially as described elsewhere 
(44) except that the avian HEV ORF2 capsid protein was used as the coating antigen and the 
residual binding of biotinylated Mabs was detected using
 
HRP-conjugated streptavidin 
(Jackson ImmunoResearch, PA) and TMB substrate system
 
(KPL, MD).  Biotinylated Mabs 
(B-Mabs) were used at a
 
dilution that gives an ELISA result of approximately 1.0 optical
 
density (OD) (in the linear portion of their binding curve to avian HEV ORF2 antigen).  
Maximum binding (no inhibition) was determined when B-Mabs were added without 
competitors.  The percentage of inhibition (PI) was calculated using the formula: 100 × 
[1 − (OD450nm of B-Mab and Mab) / (OD450nm of B-Mab)].  A B-Mab was considered 
inhibited if its binding was decreased by 40% or more.  
Purification and biotinylation of Mabs. Mabs were purified from culture 
supernatants using anti-mouse IgM (µ-chain specific) agarose affinity column (Sigma). The 
purified Mabs were dialyzed against 0.01M PBS buffer (pH 7.2) and subsequently 
concentrated to 2 mg/ml using Minicon B15 concentrator (Millipore, MA) for biotinylation 
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using EZ-link-Sulfo-NHS (N-hydroxysuccinimide)-LC-Biotin (Pierce, Rockford, IL) in 
accordance with the manufacturer’s protocol.     
Indirect immunofluorescence assay (IFA).  An IFA was used to further test the 
reactivity of Mabs with avian HEV ORF2 antigen.  Briefly, Capped RNA transcripts from a 
full-length infectious cDNA clone of avian HEV, pT7-aHEV-5, were used to transfect LMH 
chicken
 
liver cells, which supports avian HEV replication (15). Mabs were used at 10µg/ml 
and fluorescein-labeled anti-mouse IgM (KPL) was used at 1:50 dilution. The remaining 
procedures were performed as previously reported (15).  
Binding of Mabs to avian HEV virus. A modified immuno-capture RT-PCR 
method (20) was used to assess the virus binding ability of the Mabs.  Briefly, 100ng, 200ng 
and 400ng of Mabs or normal mouse IgM (κ-light chain) (Sigma) were coated on the solid-
phase of ELISA plates (Nunc
TM
, USA).  Serum samples containing avian HEV from viremic 
chickens were added at 100µl/well and incubated at room temperature for 1 hour and then at 
4°C for 12 hours.  After 6 times washing, 100µl of viral RNA extraction buffer from 
RNAgents
®
 Total RNA Isolation System (Promega) was directly added into each well.  The 
RNA was then extracted and reverse transcribed into cDNA with AMV reverse transcriptase 
(Promega).  A nested RT-PCR (39) was used to detect avian HEV viral helicase gene.  Final 
PCR products were subjected
 
to electrophoresis on a 1.2% agarose gel containing ethidium 
bromide and the second round PCR products of 221
 
bp was confirmed by DNA sequencing.  
Experiments were repeated two more times.  
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Neutralization assay. Fifteen anti-avian HEV negative chickens were divided into 5 
groups with 3 chickens each group.  From the result of virus capturing assay described above, 
we estimated that 1mg of Mabs of 1E11, 10A2 and 5G10 could bind at least 5000 genome 
equivalent (GE) of avian HEV virus.  Thus, 3000 GE of avian HEV virus was incubated with 
3mg of each of the four Mabs or normal mouse IgM.  The mixtures were incubated at room 
temperature for 1 hour and at 4°C overnight, and each mixture was subsequently injected 
equally into each of the three chickens via intravenous route.  Sera and fecal swabs were 
collected before inoculation and weekly thereafter for 5 weeks.  Viremia and fecal virus 
shedding were detected by a sensitive nested RT-PCR as previously described (39). 
Cloning and expression of avian HEV ORF2 fragment proteins. As anti-HEV 
neutralization epitopes are most likely located in the C terminal part of the ORF2 capsid 
protein (37, 42), in order to further map the epitiopes recognized by anti-avian HEV ORF2 
Mabs, four C-terminally truncated avian ORF2 fragments, designated avian ORF2-1 to avian 
ORF2-4 were constructed (Fig. 4) with recombinant plasmids containing 804 bp avian HEV 
ORF2 gene (13) as the template.  To amplify these 4 fragments, four downstream primers 
were designed using Oligo 6.0 software (MBI, Cascade, CO).  EcoR I restriction site was 
engineered into the 5’ end of these primers to facilitate subsequent cloning steps (Table 4).  
The forward primer containing BamH I site used for PCR amplification of avian HEV ORF2 
(13) was suitable for all the amplification of all four fragments.  Proofreading
 
Pfu DNA 
polymerase (Stratagene) was used for all PCR amplifications.  The PCR conditions were 
performed as following: 1 cycle at 95°C for 5 minute; 35 cycles at 95°C for 45 sec, 51°C for 
45 sec and 72°C for 45 sec; 1 cycle at 72°C for 10 minutes.  PCR products were digested and 
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purified with Wizard
®
 SV Gel and PCR Clean-Up System (Promega).  Purified DNA 
fragments were cloned into linearized pRSET-C expression vector (Invitrogen), which 
encodes a histidine tag and an Xpress™ epitope at the N terminus of the multiple cloning 
sites.  The subsequent expression of these fragments was performed essentially as previously 
described (13), except for avian HEV ORF2-1.  For the expression of avian HEV ORF2-1, 
the incubation was performed with a shaking speed of 225 rpm at 25°C for 6 hours after 
adding 1 mM IPTG.  The fusion proteins were partially purified from 100 ml of IPTG-
induced bacterial
 
cultures with the BugBuster Protein Extraction Reagent (Novagen).  
Expressions of the four truncated avian HEV ORF2 proteins were analyzed by Western blot 
(13) using 1:5000 diluted HRP-conjugated anti-Xpress epitope Mabs (Invitrogen) or 1:1000 
diluted polyclonal anti-avian HEV chicken sera.   
Mapping of neutralizing epitopes on avian HEV capsid protein and comparison 
with that of Sar-55 human HEV. The epitopes recognized by the Mabs were mapped by 
Western blot.  Each of the partially purified truncated avian HEV ORF2 proteins was 
separated by 15% SDS–PAGE in non-reducing or reducing conditions
 
and electrophoretically 
transferred onto a 0.2µM polyvinyliden difluoride (PVDF) membrane (Bio-Rad).  The 
membranes were blocked with 0.01M PBST containing 2.5% dry milk overnight with slow 
shaking and then incubated
 
for 1 hour at room temperature with each of the Mabs at 4µg/ml.  
Normal mice sera (1:100) and mouse anti-avian ORF2 sera (1:1000) were used as negative 
and positive controls, respectively.  After washing the membranes, HRP-goat anti-mouse IgM 
(µ chain specific) (1:2000) was added and incubated for 1 hour.  The immunocomplexes
 
were 
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detected using 3, 3'-Diaminobenzidine (DAB) Enhanced Liquid Substrate System 
tetrahydrochloride (Sigma).  
The identified neutralizing epitope positions on avian HEV ORF2 protein were 
compared to that identified on human HEV Sar-55 ORF2 protein (36, 37, 45).  The 268 aa 
avian HEV ORF2 protein and the corresponding 267 aa Sar-55 ORF2 protein (13) were 
aligned with MegAlign program (DNAstar package, DNA STAR Inc., Madison, WI) by 
ClustalW alignment with the selection of Fast-Approx and BLOSUM 30 matrix.  
Results 
Production and characterization of Mabs. Four hybridoma clones secreting Mabs 
designated 7B2, 1E11, 10A2, and 5G10 (all IgM isotypes with κ-light chain) against avian 
HEV ORF2 capsid protein were obtained from four different parental fusion clones, and 
confirmed by detection of the hybridoma surface IgM profiles (MFI for 7B2, 1E11, 10A2, 
and 5G10 is 107.8, 157.9, 308.6 and 354.4, respectively) (Table 1). Since IgM antibodies 
have poly-reactivity (3, 19), the specificity of these Mabs was first tested with different 
antigens.  As seen in Fig.1, all Mabs reacted specifically with avian HEV ORF2 capsid 
protein but not with avian HEV ORF2 peptides, the ORF2 capsid proteins of genotype 1 
human and genotype 3 swine HEVs, PCV capsid protein, or PRRSV N protein.  At 1µg, the 
OD490nm values reacting with avian HEV capsid protein were 2.5, 2.3, 2.2 and 1.1 for 
5G10, 10A2, 1E11 and 7B2, respectively. The 7B2 had the lowest binding affinity whereas 
5G10 had the highest. 1E11, 10A2 had similar binding affinity to 5G10.  
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The binding of B-7B2 to avian HEV ORF2 protein was inhibited by homologous 7B2 
at 84.8%.  Complete inhibition was obtained for heterologous 1E11 and 10A2 with the 
percentage of inhibition at 95.2 and 96.8, respectively (Table 2).   The binding of B-1E11 and 
B-10A2 to avian HEV ORF2 protein was completely inhibited by the homologous Mabs, and 
inhibited each other (93%-98% inhibition). In contrast, 7B2 can only partially inhibit the 
binding of B-1E11 and B-10A2 to the avian HEV ORF2 protein at 54.4% and 63.1%, 
respectively.  These results suggested that 7B2, 1E11 and 10A2 may share the same or 
overlapping epitopes.  There was no significant inhibition (<19%) between 5G10 and the 
other three Mabs, indicating that 5G10 likely recognizes a different epitope.   
To determine whether Mabs could recognize the native avian HEV ORF2 capsid 
protein on viral particles, LMH chicken
 
liver cells were transfected with capped RNA 
transcripts from a full-length infectious clone of avian HEV (15). The reactivity of Mabs with 
the native avian HEV ORF2 protein in transfected LMH cells was examined by IFA.  The 
positive control polyclonal anti-avian HEV serum reacted with avian HEV ORF2 proteins on 
the transfected cells (Fig. 2A), while negative chicken sera did not react with the transfected 
cells (Fig. 2C).  At the concentration of 10µg/ml, only 5G10 showed
 
reproducible binding to 
the native avian HEV ORF2 capsid protein (Fig. 2B). None of the other three Mabs reacted 
with the transfected cells (data not shown).  
Mabs reacted with avian HEV particles. To determine whether
 
Mabs could capture 
circulating avian HEV particles, a sensitive nested RT-PCR (39) was used to detect the 
presence of avian HEV captured by the Mabs. As shown in Fig.3, 1E11, 10A2 and 5G10, 
when coated at 200ng or 400ng per well, captured avian HEV.  At 100ng/well, 5G10 was 
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also able to capture avian HEV. Neither 7B2 nor control mouse IgM could capture the virus 
with the amounts used.  
Neutralization of avian HEV by Mabs. Since there is no cell culture available to 
support the replication of avian HEV, an animal-based neutralization assay was used in this 
study to examine the ability of Mabs to neutralize avian HEV as previously established (36).  
Chickens that were inoculated with avian HEV incubated with
 
either normal mouse IgM or 
7B2 became infected one week after inoculation, as evidenced by fecal virus shedding and 
viremia (Table 3).  In contrast, chickens
 
inoculated with avian HEV incubated with 1E11, 
10A2 and 5G10 did not have detectable avian HEV RNA in sera or feces until 3 weeks post-
inoculation. These results suggested 1E11, 10A2 and 5G10 could at least partially neutralize 
avian HEV and the infection caused by non-neutralized virus or escaped virus was 
significantly delayed.  
Expression and purification of avian HEV ORF2 fragments.  Avian
 
HEV ORF2-
1, 2, 3, 4 fragments were amplified by RT-PCR (Fig.5A), and subsequently cloned into 
pRSET-C expression vector. The recombinant clones were confirmed by DNA sequencing.  
After 3 hours incubation in a shaker with 250 rpm at 37°C, the ORF2-2, 3, 4 proteins with 
expected sizes of approximately 23, 18, 16 kDa, respectively, were expressed and partially 
purified (Fig. 5B).  Two proteins with the sizes of approximately 28kDa and 16.5kDa were 
obtained when bacterial cells transformed with avian
 
HEV ORF2-1 plasmids were induced 
with IPTG and cultured at 25°C in a shaker at 225 rpm for 6 hours (Fig. 5B).  All fusion 
proteins were expressed predominantly as inclusion bodies in bacterial cells. Western blot 
analysis using a monoclonal
 
antibody against the Xpress epitope confirmed the expression of 
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these recombinant ORF2 proteins (Fig. 5C).  The expressed proteins were also recognized by 
anti-avian HEV positive chicken sera in Western blot (Fig. 5D). 
Epitope mapping. To map the epitopes recognized by the Mabs, the purified avian 
HEV ORF2 fragment proteins were probed with each Mab in Western blot analyses.  As 
shown in Fig.6, all Mabs recognized ORF2 and ORF2-1 proteins, but not the other proteins, 
suggesting that at least one epitope is located between aa residues 175 and 232 (Fig.4 and 
Fig.6).  In addition to the ORF2 and ORF2-1 proteins, 5G10 also recognized the ORF2-2 
protein, suggesting that the recognized epitope by 5G10 is located between aa residues 138 
and 175.  The reaction pattern for each MAb was same when avian
 
HEV ORF2 fragment 
protein samples were loaded in reducing sample buffer (data not shown). These results were 
in agreement with the competitive ELISA results (Table 2), which implied that 7B2, 1E11, 
10A2 and 5G10 recognized two different epitopes.  
The avian HEV ORF2 protein has similar antigenic profiles to that of genotype 1 
human HEV (Sar-55 strain), and the relative positions of the predicted four antigenic 
domains on ORF2 protein are similar between avian HEV and Sar-55 HEV (13). It has been 
reported that the neutralizing epitope on Sar-55 ORF2 protein was between aa 459 and 607 
(8, 45) or aa 66 to aa 214 (Fig.7), and it covered all aa residues in domain II and most of aa 
between domains II and III (Fig. 7). Although this neutralizing epitope spans a 148 aa region 
in length, it is the shortest that can be recognized by the corresponding neutralizing Mabs (8, 
45).  In this study, the neutralizing epitope defined by 5G10 was between aa residues 138 and 
175 and covered most of aa residues in domain II and part of aa between domains II and III 
(Fig. 7). The neutralizing epitope recognized by 7B2, 1E11, 10A2 was between aa residues 
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175 and 232 and covered all the aa of domain III and part of aa between domains II and III 
(Fig. 7).  Therefore, the relative positions of the two neutralizing epitopes on avian HEV 
capsid protein identified in this study are similar to the mapped neutralizing epitope on Sar-
55 ORF2 protein (Fig. 7).  
Discussion 
Avian HEV has been classified in the same genus Hepevirus as the mammalian HEVs 
(11).  There exist similar antigenic profiles between avian HEV and human HEV ORF2 
capsid proteins (13).  Numerous studies have demonstrated that immunization of monkeys 
with recombinant ORF2 protein of human HEV expressed in SF9 cells or bacterial cells 
confer protection against HEV infection by inducing strong antibody responses (10, 17, 21, 
22, 31, 43).  The Sar-55 HEV derived recombinant ORF2 protein has been used as candidate 
vaccine in phase II/III field trials in Nepal (30).  Our recent data showed that immunization of 
chickens with bacterially expressed avian HEV ORF2 protein also induce protective antibody 
response (Guo et al., Vaccine. Submitted).  The delineation of the neutralizing epitopes on 
avian HEV ORF2 capsid protein provided direct evidence that protection against avian HEV 
infection by immunization with avian HEV ORF2 protein was likely due to the induction of 
neutralizing antibodies.  
Four anti-avian HEV ORF2 Mabs of IgM class were produced.  It is unclear why only 
IgM isotypes were produced in this study, however inefficient switching was not likely since 
after the 2
nd
 immunization, mouse anti-avian HEV ORF2 serum IgG titer reached about 
1:100,000 in all immunized mice (data not shown).  The competitive ELISA results indicated 
that 7B2, 1E11 and 10A2 recognize the same or overlapping epitopes and 5G10 recognizes a 
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different one.  These results were further confirmed by the epitope mapping study.  It is not 
surprising that 7B2 only partially inhibited the binding of B-1E11 and B-10A2 to the avian 
HEV ORF2 protein, since the binding affinity of  7B2 is almost two-fold lower than 1E11 
and 10A2 (Fig. 1). 
Two antigenic epitopes common to avian and human HEVs mapped previously by 
using synthetic peptides (12) were not recognized by these Mabs (Fig.1).  Similarly, none of 
these Mabs recognized swine or human HEV recombinant ORF2 proteins, indicating that the 
corresponding epitopes recognized by these Mabs were unique to avian HEV ORF2 protein.  
If these epitopes are predominant neutralizing epitopes, cross-species neutralizing epitopes on 
HEV ORF2 proteins may not exist.   
The IFA results using transfected LMH cells suggested the epitope recognized by 
5G10 was intact whereas the epitopes recognized by 7B2, 1E11 and 10A2 were either 
damaged or not exposed on native avian HEV ORF2 proteins. It is important to point out 
that, upon transfection into the LMH cells, the RNA transcripts of the avian HEV infectious 
clone only have a limited level of replication and the replicating virus does not spread from 
cell to cell (15), and thus the IFA is much less sensitive to assess the binding between Mabs 
and virus capsid protein. The fact that 1E11 and 10A2 can capture circulating avian HEV 
particles suggested that the corresponding epitopes on viral ORF2 protein are exposed and 
recognized. The viral capturing ability of these Mabs was specific and affected by their 
affinity, as normal mouse IgM and lower affinity 7B2 did not capture any detectable avian 
HEV, whereas the higher affinity Mab 5G10 could capture virus in a relatively low amount.  
The demonstrated virus capturing ability of Mabs 1E11, 10A2 and 5G10 suggested that these 
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Mabs can neutralize virus. It has been reported that two anti-Sar-55 HEV chimpanzee Mabs 
can capture and neutralize Sar-55 HEV, whereas other Mabs without virus capturing ability 
cannot neutralize the virus (37).   
It is not surprising that even at the same used amount as 1E11 and 10A2, 7B2 could 
not neutralize avian HEV due to its low affinity and virus capturing ability. The results that 
1E11, 10A2 and 5G10 can only partially neutralize avian HEV proved that high levels of 
Mabs or convalescent anti-HEV sera are needed for complete virus neutralization (8, 42), and 
this could explain why some infected birds with low level of avian HEV antibody response 
are still viremic and shed virus in feces (6, 15, 39). 
In a typical induction (1mM IPTG) and incubation condition (37°C and 250 rpm), the 
predicted 28 kDa avian
 
HEV ORF2-1 fragment protein was not produced, but a significant 
amount of 16.5 kDa protein (data not shown). After excluding the possibilities of potential 
contamination with avian HEV ORF2-4 plasmid, which expresses an estimated 16 kDa 
protein, and the potential premature stop of avian HEV ORF2-1 gene introduced during RT-
PCR and cloning steps, we speculate that the predicted 28 kDa avian
 
HEV ORF2-1 fragment 
protein may be quickly degraded.  To optimize this protein’s expression, we performed the 
induction and incubation conditions for ORF2-1 fragment protein at lower temperature and 
shaking speed (25°C and 225 rpm), since inclusion body proteins are easier to be improperly 
folded or irremediably damaged and thus become target for degradation when bacterial cells 
grow at high speed and high temperature (5, 38). The use of low temperatures also has the 
combined advantages of slowing down transcription and translation rates and of reducing the 
strength of hydrophobic interactions that contribute to protein misfolding (4). Under the 
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modified expression condition for ORF2-1 fragment protein, the predicted 28 kDa protein 
was produced (Fig. 5B), indicating that the modified expression conditions significantly 
reduce the degradation rate of the expected 28 kDa protein. The specific truncation of avian 
HEV ORF2-1 fragment protein might produce a favorable conformation targeted for 
degradation, which did not occur in other ORF2 fragments.    
The epitope defined by 5G10 was between aa residues 138 and 175. However, since 
the peptide 2 derived from the entire domain II (aa 123–154) could not react with 5G10, the 
actual epitope recognized by 5G10 could be between aa 154 and 175 if it is linear.  The 
epitope recognized by 7B2, 1E11 and 10A2 was between aa 175 and 232.  Similarly, since 
the peptide 3 representing entire domain III (aa 217–aa 227) failed to react with 7B2, 1E11 
and 10A2 (Fig. 1, 7), amino acids of peptide 3 are not critical components of the epitope 
recognized by these three Mabs or the recognized epitope is probably conformational.  
The reported human HEV Sar-55 neutralizing epitope is the only major protective 
epitope mapped on human HEV and it is the essential component of human HEV 
recombinant ORF2 protein vaccine (30, 37).  Since the two neutralizing epitopes identified 
on avian HEV ORF2 protein in this study are nearly within the corresponding position of the 
Sar-55 neutralizing epitope, these avian HEV neutralization epitopes could also be the major 
protective epitopes on avian HEV ORF2 protein.  However, neither of the two epitopes was 
conserved among avian, human and swine HEVs, as the corresponding Mabs failed to react 
with Sar-55 or swine HEV ORF2 antigens.  This is not surprising, since the aa sequence 
identity of the epitope is only approximately 16% among avian, Sar-55 and swine HEVs.  
Two different epitopes on ORF2 protein of a genotype I HEV (strain XM) were identified by 
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Mabs 8C11 and 8H3 as protective neutralizing epitopes, as rhesus monkeys inoculated with 
the virus pretreated with these two Mabs had delayed onset of fecal virus shedding (2, 42).  
Although the detailed positions of these two epitopes were not mapped, they are within the 
same region of that of Sar-55 HEV, which is also a genotype 1 HEV (11).  This suggests that 
there are likely more than one protective neutralizing epitopes for human HEV, which is in 
agreement with our findings in this study on avian HEV ORF2.  
The avian HEV ORF2 protein used for immunization for the production of Mabs was 
purified from denatured form (12), thus the Mabs likely recognize linear epitopes, which was 
further confirmed by Western blot results.  However, the originally-thought linear protective 
epitope on Sar-55 HEV ORF2 protein (36, 37, 45) has now been considered as 
conformational since it is very stable and resistant to heat treatment and reducing agents (36, 
37).  Thus, whether the neutralizing epitopes identified on the avian HEV ORF2 are 
conformational or linear warrants further investigation.  
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FIGURE LEGENDS 
Fig.1. Reactivity of anti-avian HEV ORF2 Mabs with different antigens. ELISA plates coated 
with different antigens were incubated with indicated concentrations of Mabs and the bound 
Mabs were detected with HRP-conjugated anti-mouse IgM, µ chain specific. Each point 
represents the mean value (±S.E.M.) of the OD490nm obtained from duplicate ELISA results. 
Fig. 2. Immunofluorescent staining of LMH chicken liver cells transfected with capped RNA 
transcripts from avian HEV cDNA infectious clone, pT7-aHEV-5 (15).  (A) transfected cells 
stained with polyclonal anti-avian HEV chicken serum. (B) transfected cells stained with 
5G10. (C) transfected cells stained with negative chicken serum. 
Fig. 3. Capture of circulating avian HEV particles with Mabs.  Nested RT-PCR was used to 
detect bound virus as described (39).  Lane M: 1 kb ladder; lanes 1-3: coated with 100ng, 
200ng and 400ng per well of 5G10, respectively; lanes 4-6: coated with 100ng, 400ng and 
200ng per well of 10A2, respectively; lanes 7-9: coated with 100ng, 400ng and 200ng per 
well of 1E11, respectively; lanes 10-12: coated with 100ng, 200ng and 400ng per well of 
7B2, respectively; lanes 13-15: coated with 100ng, 200ng and 400ng per well of normal 
mouse IgM, respectively.   
Fig. 4. Schematic diagram of C-terminal-truncated avian HEV ORF2 protein fragments. 
Recombinant plasmid containing avian HEV ORF2 was used as the template for the 
construction of the four C terminally truncated ORF2 fragments as described in the text.  
Fig. 5. Expression of avian HEV ORF2 protein fragments. (A) PCR amplification of avian 
HEV ORF2 fragments. M: DNA marker; lane 1 to 4: avian HEV ORF2-4, 3, 2, 1, with 
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expected sizes of 330, 414, 525, 696 bp, respectively. (B) SDS-PAGE of partially purified 
avian HEV ORF2 fragment proteins. M: Protein marker; lanes 1 to 4: avian HEV ORF2-4, 3, 
2, 1, with predicted sizes of 16, 18, 23, 28 kDa, respectively; lane 5: 32 kDa avian HEV 
ORF2 protein (13). Avian HEV ORF2-1 had two major forms: a predicted 28 kDa, and a 
partially degraded 16.5 kDa. (C) Western blot of expressed products by using HRP-
conjugated anti-Xpress epitope Mab. (D) Western blot analysis of the expressed proteins with 
ant-avian HEV chicken serum.  Lanes in (C) and (D) are the same as in (B). 
Fig. 6. Epitope mapping on avian HEV ORF2 capsid protein by Western Blot. Partially 
purified avian HEV ORF2 fragment proteins were separated on SDS-PAGE in non-reducing 
conditions and transferred to PVDF membranes and reacted with (A): 7B2; (B): 1E11; (C) 
10A2; (D) 5G10.  M: Protein marker; lanes 1 to 5: Mabs reacted with avian HEV ORF2 and 
avian HEV ORF2-1, 2, 3, 4, respectively. 
Fig. 7. Comparison of neutralization epitopes on avian HEV and human HEV Sar-55 ORF2 
proteins.  Amino acid sequences of avian HEV ORF2 protein and its corresponding region of 
Sar-55 HEV were aligned.  Dots represent identical residues.  Dashes represent deletions. 
Two neutralizing epitopes on avian HEV ORF2 protein were boxed with solid and dot lines.  
The reported neutralizing epitope on Sar-55 HEV ORF2 protein (45) was underlined.  The 
predicted four antigenic domains (I, II, III, IV) on avian HEV ORF2 capsid protein (13) were 
also indicated.  
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Table 1. Characterization of hybridomas 
a: normalized mean fluorescence intensity (MFI) of each hybridomas analyzed by flow 
cytometry; b: estimated from Fig.1; c: reactivity of purified Mabs with avian HEV viral 
ORF2 protein in IFA (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hybridomas Isotype MFI
a
 Affinity
b
 IFA
c
 
7B2 IgM/κ 107.8 Low − 
1E11 IgM/κ 157.9 High − 
10A2 IgM/κ 308.6 High − 
5G10 IgM/κ 354.4 Highest + 
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Table 2.  Inhibition of the binding of biotinylated Mabs (B-Mabs) to avian HEV ORF2 
capsid protein 
Inhibition by a non-labeled antibody (%) 
Biotin-labeled Mab 
7B2 1E11 10A2 5G10 
7B2 84.8 95.2 96.8 18.7 
1E11 54.4 94.5 93.1 11.8 
10A2 63.1 97.7 96.3 12.2 
5G10 8.3 16.1 14.3 98.2 
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Table 3.  Detection of avian HEV RNA in sera and fecal swabs from chickens inoculated 
with mixtures of Mab and virus 
No. of positive sera (fecal swabs)/ total no. tested at indicated WPI 
Groups 
0 1 2 3 4 5 
NMIgM 0(0)/3 3(3)/3 3(3)/3 3(3)/3 3(3)/3 2(2)/3 
7B2 0(0)/3 3(3)/3 3(3)/3 3(3)/3 3(3)/3 2(1)/3 
1E11 0(0)/3 0(0)/3 0(0)/3 3(1)/3 3(3)/3 2(2)/3 
10A2 0(0)/3 0(0)/3 0(0)/3 2(2)/3 3(3)/3 1(3)/3 
5G10 0(0)/3 0(0)/3 0(0)/3 3(3)/3 3(3)/3 2(1)/3 
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Table 4. Synthetic oligonucleotide primers used for avian HEV ORF2 fragments 
amplification 
Primer Sequence (5' → 3') Position (nt) 
Avian HEVORF2U GGGGGATCCAGTACATGTACGGCCGGCCTG 1-22 
Avian HEVORF2-1L GGGGAATTCGCCAGTGTGGTGTGCCAAAAACC 673-696 
Avian HEVORF2-2L GGGGAATTCGTAGAAATACCCAGCGCCCTGGG 502-525 
Avian HEVORF2-3L GGGGAATTCATCCACTGTTGCCTTCGTCCAGG 391-414 
Avian HEVORF2-4L GGGGAATTCGGCCCCAAAGTACCCCTGTGACC 307-330 
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CHAPTER 6. EGG WHITES FROM EGGS OF CHIKCENS EXPERIMENTALLY 
INFECTED WITH AVIAN HEPATITIS E VIRUS CONTAIN INFECTIOUS VIRUS 
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Abstract   
Avian hepatitis E virus (avian HEV) is genetically and antigentically related to human 
HEV. Vertical transmission of HEV has been reported in humans, but not animals. In this 
study, we demonstrated that avian HEV RNA was detected by RT-PCR in egg white samples 
of eggs laid by chickens experimentally infected with avian HEV. To determine the 
infectivity of virus detected by RT-PCR in egg white, two groups of chickens were inoculated 
with either PCR-positive egg white sample or PCR-negative normal egg white sample. The 
results showed that the avian HEV in egg white remained infectious as evidenced by the 
appearance of viremia, fecal virus shedding and seroconversions in chickens inoculated with 
the PCR-positive egg white sample, but not in the chickens inoculated with the PCR-negative 
normal egg white sample. To assess the possibility of vertical transmission of avian HEV, 
two chickens were inoculated with an infectious avian HEV stock and housed with two 
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roosters to produce embryonated eggs. Batches of embryonated eggs collected before and 
after virus inoculation were hatched and the hatched chicks were monitored for evidence of 
avian HEV infection. However, no virus was detected in samples collected from hatched 
chicks throughout this study, suggesting avian HEV could not complete the vertical 
transmission cycle. The finding of moderate amounts of infectious avian HEV in egg white 
might explain the significant level of IgG anti-HEV seroprevalence in healthy humans after 
repeated consumption of eggs containing avian HEV.  
Introduction  
Hepatitis E virus (HEV), which causes epidemic and sporadic self-limiting acute 
hepatitis, is an important public health disease in many developing countries where sanitation 
condition is poor (Purcell & Emerson, 2001). Although, only sporadic cases were reported in 
the industrialized countries, anti-HEV antibodies are detected in 1–20 % of the general 
population in these countries (Purcell & Emerson, 2005). Domestically acquired hepatitis E 
cases have recently been reported in industrialized countries including the United States, 
United Kingdom, French and Japan (Amon et al., 2006; Sadler et al., 2006; Mansuy et al., 
2004; Mizuo et al., 2005). The mortality associated with HEV infection is generally as low as 
less than 1% in the general population, however, in pregnant women the mortality rate can 
reach up to 20 % with unknown reason (Purcell & Emerson, 2001). HEV was also reportedly 
transmitted from infected mothers to their babies causing significant perinatal morbidity and 
mortality (Kumar et al., 2004; Singh et al., 2003; Kumar et al., 2001; Khuroo, et., 1995).   
Hepatitis E is a zoonosis (Meng 2005; Tei et al., 2003; Tamada et al., 2004). Anti-
HEV antibodies have been detected in a number of animal species including cattle, pigs, 
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chickens, sheep, goats, primates and rodents (Favorov et al., 1998; Tien et al., 1997; 
Arankalle et al., 1994; Kabrane-Lazizi et al., 1999), but thus far only two animal strains of 
HEV, swine HEV from pigs and avian HEV from chickens, have been definitively isolated 
and characterized (Meng et al.,1997; Haqshenas et al., 2001).   
Cross-species infections have been demonstrated,
 
as a US-2 strain of human HEV 
infected specific-pathogen-free (SPF)
 
pigs and a swine HEV strain infected nonhuman 
primates (Halbur et al., 2001; Meng et al.,1998a). Swine have been considered as an 
important source of infection for swine veterinary workers and swine farmers (Zheng et al., 
2006; Meng et al., 2002; Kasorndorkbua et al., 2005). However,
 
the detection of a high level 
of anti-HEV prevalence in human
 
populations who have no history of exposure to pigs 
suggests
 
that multiple sources of exposure may exist (Meng et al., 2002).  
Rodents could serve a reservoir for HEV, since they are widely distributed in urban as 
well as rural environments (Emerson & Purcell, 2003), however, HEV has not yet been 
isolated from rodents even though wild-caught rodent populations are seropositive for HEV 
(Emerson & Purcell, 2003; Stoszek et al., 2006). HEV transmission via the consumption of 
undercooked or raw pig liver or deer meats has been reported, and could be a source for the 
observed high anti-HEV prevalence (Tei et al., 2003; Tamada et al., 2004). 
Rhesus monkeys are frequently used as the animal model for HEV study, however 
infected pregnant monkeys failed to transmit the virus to offspring (Tsarev et al., 1995). An 
attempt to demonstrate vertical transmission of HEV from pregnant gilts to their pigs was 
unsuccessful (Kasorndorkbua et al., 2003). Avian HEV was first isolated from chickens with 
hepatitis-splenomegaly (HS) syndrome in the United States, and was shown to be genetically 
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and antigentically related to human HEV (Haqshenas et al., 2001, 2002; Huang et al., 2004). 
Avian HEV infection in chickens has been proven to be a good model system to study HEV 
replication and pathogenesis (Billam et al., 2005). The question of whether or not HEV can 
be vertically transmitted under controlled experimental conditions remains unknown. 
In this study, we utilized the avian HEV and the chicken model system to investigate 
the feasibility of vertical HEV transmission. We demonstrated that avian HEV can be passed 
in egg whites in infected chickens and that the virus in the egg white is infectious. An 
experimental vertical transmission study was also attempted.    
Material and Methods  
Avian HEV virus. Since avian HEV can not be propagated in vitro, an infectious 
stock of avian HEV was produced by intravenously inoculating chickens with 200 µl of the 
avian HEV with a titer of 10
3
 50% chicken infectious doses
 
(CID50) per ml (Sun et al., 2004). 
The avian HEV infectious stock containing 1×10
4
 genome equivalent (GE)/ml in feces 
suspension was obtained and used for chicken inoculation in this study. An egg white sample 
containing avian HEV with a titer of 1×10
4
 GE/ml were also used for infecting chickens.  
Detection and titration of avian HEV in egg white. Intact eggs were collected from 
the chicken infection study aimed to generate avian HEV infectious stock. The detection of 
avian HEV virus in eggs was performed with a modified protocol that routinely used for 
avian influenza virus detection in the Veterinary Diagnostic Laboratory of Iowa State 
University. All eggs shells were washed with 70% ethanol before the separation of white and 
yolk. White samples were 1:3 diluted with 0.01M PBS buffer (pH 7.2) and centrifuged for 5 
min at 5,000 g. 100 µl of the supernatants were used for RNA extraction with RNeasy Mini 
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Kit (Qiagen, CA). Total RNA was eluted with 20 µl DEPC-treated water. Reverse 
transcription (RT) with an avian HEV-specific primer was performed
 
at 42 °C for 60 min in 
the presence of a master mixture consisting
 
of 10 µl of total RNA, 0.25 µl of AMV reverse 
transcriptase (Promega), 1 µl of 10 µM
 
antisense primers, 0.5 µl of RNase inhibitor, 4 µl of 5 
× RT buffer, and 1 µl
 
of 10 mM dNTP.  
The resulting cDNA was
 
amplified by a nested RT-PCR with Taq DNA polymerase
 
(Promega) and two pairs of avian HEV specific primers targeting partial viral helicase gene 
as described previously (Sun et al., 2004) with the following modifications. The first round 
PCR parameters were 95 °C for 5
 
min, followed by 38 cycles of amplification at 94 °C for
 
1 
min for denaturation, 52 °C for 1 min for annealing, and
 
72 °C for 1 min for extension, with a 
final incubation
 
period at 72 °C for 7 min. For the second round PCR, 5 µl of the first round 
PCR products were used as the templates and the annealing temperature was increased to 53 
°C and the amplification cycles were changed to 35. PCR was performed using the 
Mastercycler Personal (Eppendorf, NY). The final PCR products were examined
 
on a 1.0% 
agarose gel containing 1.0 µg.ml
-1
 ethidium bromide. 
The genomic titer of avian HEV RNA in the positive egg white samples was 
determined similarly as the titration of swine HEV genomic RNA (Meng et al., 1998b). 
Briefly, positive egg white samples were 10-fold diluted with 0.01 M PBS buffer (pH 7.2) 
and each diluent was used for RNA extraction and nested RT-PCR as described above. One 
genome equivalent (GE) was defined as the number of viral genomes present in the highest 
10-fold dilution that is positive by the nested RT-PCR (Meng et al., 1998b).  
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Specific-Pathogen-Free (SPF) chickens. Thirty-eight 22-week-old SPF hens and two 
22-week-old SPF roosters (M&C Anderson Pullets, Sioux Rapids, IA), negative for 
antibodies to avian HEV, were used in this study. All chickens were tagged and divided into 
3 groups. Group 1 and 2 each had 18 hens (ID#1–18 in Group 1, and ID#19 – #36 in Group 
2) and chickens in each group were housed in 6 cages with 3 hens per cage. Group 3 
contained 2 hens (ID#37, #38) and 2 roosters (ID#39, #40) and was housed together in a 
room.  
Experimental inoculation and sample collection. All chickens in group 1 were each 
inoculated intravenously with 400 µl of the egg white sample #13 with a titer of 1×10
4
 
GE/ml. All chickens in group 2 were each similarly inoculated with 400 µl of a normal egg 
white sample (negative for avian HEV RNA by RT-PCR). The two hens in Group 3 were 
each inoculated intravenously with 400 µl an infectious stock of avian HEV with a genome 
titer of 1×10
4
 GE/ml. Serum and fecal samples from each chicken were collected weekly for 
a total of 5 weeks and 100 µl of each sample were used for the detection of avian HEV 
viremia and fecal virus shedding by nested RT-PCR.  
Egg hatching. Eggs were collected daily from Group 3 chickens starting from one 
week before virus inoculation to 5 weeks post inoculation (WPI). Eggs collected during the 
same week period were hatched as one batch in a RX1 incubator with automatic egg turning 
(Lyon Electric Company, CA). Temperature and humidity were adjusted according to the 
manufacture’s instruction. A total of 6 batches of eggs were hatched. Each batch of chicks 
was housed separately and monitored daily for fecal virus shedding and viremia for one week 
before necropsy.      
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Necropsy and pathology. It has been shown that chicken liver is the major tissue that 
develops gross lesions after avian HEV infection (Billam et al., 2005). Necropsy was 
performed on 3 chickens from each of the Groups 1 and 2 at 1 to 4 WPI and on the remaining 
6 chickens in each of the two groups at 5 WPI. Gross lesions in the livers were recorded by 
digital camera. Bile samples were collected from the necropsied chickens for the detection of 
viruses. The livers were also collected for virus detection from all chicks necropsied at seven 
days after hatch.  
Sequencing and sequence analysis. Positive egg white samples were amplified by 
RT-PCR using the high-fidelity ProofStart DNA polymerase (Qiagen, CA). The final PCR 
products of 221bp were sequenced for both strands using ABI 3730 DNA Analyzer (Applied 
Biosystems, CA) at Iowa State University DNA Facility (Ames, Iowa) to confirm the identity 
of the viruses
 
recovered from the inocula. Sequences were aligned and analyzed using the 
MegaAlign program (DNA STAR Inc., Madison, WI). 
ELISA assay. Chicken serum samples from all the 14 chickens in Groups 1 to 3 that 
were continuously monitored for 5 weeks were tested for anti-avian HEV ORF2 antibody by 
an indirect ELISA as described (Guo et al., 2006). Briefly, ELISA
 
plates were coated with 
avian HEV ORF2 antigens (100 ng/well) overnight at 4°C. After washing and blocking, 100 
µl 1:100 diluted chicken sera were added to each well in duplicate and
 
incubated for 1 hr. 
HRP-conjugated goat anti-chicken IgY-HRP conjugate (Jackson ImmunoResearch lab) was 
added as detecting antibody. O-phenylenediamine dihydrochloride (OPD) (Sigma) was used 
for colorimetric reaction.   
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Detection of serum lactate dehydrogenase (LDH). It has been demonstrated that 
avian HEV infection results in the elevation of serum LDH in infected chickens (Billam et 
al., 2005).  Cytotoxicity LDH detection kit (Roche Applied Science, IN) was used to measure 
the LDH levels in sera from the chickens that were continuously monitored for 5 weeks after 
virus inoculation. Briefly, chicken sera were 1:10 diluted with freshly prepared 1% bovine 
serum albumin (BSA) in 100mM PBS (pH 7.5). Chicken LDH standard (Sigma) was also 
serially diluted and used to establish a standard curve. Freshly mixed catalyst and dye 
solution (100 µl) provided in the kit were added into each well of 96-well ELISA plate, 
followed by adding 100 µl of diluted serum samples and chicken LDH in duplicates. The 1% 
BSA diluent was added and used as a background control.  After incubation at room 
temperature for 20 min, the reaction was stopped by adding 1N HCl (50 µl/well) and 
measured with ELISA reader at 490 nm. The absolute LDH activity in chicken sera was 
inferred from the LDH standard curve. 
Statistical analysis: Statistical analysis was performed as described previously (Guo 
et al., 2006). P values of ≤0.05 were considered significant. 
Results  
Detection of avian HEV RNA in egg white  
A total of 20 eggs (#1 to #20) were collected between 3 and 4 WPI from laying 
chickens during the course of an experiment aimed to generate an infectious stock of avian 
HEV.  Egg whites were tested for avian HEV RNA by an avian HEV-specific nested RT-
PCR assay. Five of the 20 eggs (#4, 13, 14, 16, 17) had detectable avian HEV RNA in egg 
white (Fig. 1A, B). Positive egg white samples were further titrated by a semi-quantitative 
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nested RT-PCR. Egg white sample #4 and #14 contained 100 GE/ml of avian HEV RNA 
(Fig. 1C, E), sample #13 had 1×10
4
 GE/ml of avian HEV RNA (Fig. 1E), and sample #16 
and #17 both had 1×10
3
 GE/ml of avian HEV RNA (Fig. 1D). The PCR products amplified 
from the five egg white samples were sequenced, and sequence analyses confirmed that the 
viruses recovered from egg white were originated from the inocula. The avian HEV 
sequences from egg white sample #4, #13, #14, #16, and #17 were deposited in GenBank 
database with the accession numbers of DQ660974, DQ660975, DQ660976, DQ660977, 
DQ660978, respectively. 
Egg white contains infectious avian HEV   
Sera, feces and bile samples collected from the three groups of chickens were tested 
for the presence of avian HEV RNA by a nested RT-PCR. In group 1 chickens inoculated 
with PCR-positive egg white sample #13, viremia and fecal virus shedding were detected 
beginning from 3 WPI (Table 1). Virus was also detected variably in bile samples collected 
during necropsies in Group 1 chickens. However, viremia and virus shedding in feces or bile 
were not detected from Group 2 chickens, which were inoculated with normal egg white 
samples. Both hens in Group 3 that received an infectious stock of avian HEV had detectable 
viremia and fecal virus shedding starting at 1 WPI.   
Anti-avian HEV antibody response 
Prior to inoculation, all chickens in the 3 groups were seronegative
 
for avian HEV. 
Anti-avian HEV IgG was detected at 2 WPI in both hens in Group 3 that were inoculated 
with an avian HEV infectious stock and remained seropositive throughout the study (Fig. 2). 
For the 6 chickens from Group 1 that were continuously monitored for 5 weeks, anti-avian 
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HEV IgG was detected at 4 and 5 WPI. As expected, anti-avian HEV antibody was not 
detected from any of the chickens from Group 2, which were inoculated with normal egg 
white samples.  
Serum LDH 
It has been shown that serum LDH enzyme was increased in chickens after 
intravenous or oronasal inoculation with avian HEV (Billam et al., 2005). In this study, the 
dynamics of serum LDH levels in the 6 continuously monitored chickens from Group 1 
(inoculated with PCR-positive egg white sample #13) and in the 2 continuously monitored 
hens from Group 3 (inoculated with avian HEV infectious stock as positive control) were 
similar to that in the 6 continuously monitored chickens from Group 2 that were inoculated 
with normal white samples, with the exception at 3 WPI, 1WPI, respectively (Fig. 3), in 
which the LDH level in Group 1 and Group 3 was significantly higher than that in Group 2 (P 
value of 0·015 and 0.017, respectively.). 
Attempt to detect avian HEV from hatched chicks  
As shown in table 2, 11 to 13 eggs were laid weekly by the 2 hens in Group 3. The 
fertility of each batch of eggs reached from 91% to 100%. The hatchability of eggs collected 
from 1 week before virus inoculation and 4 weeks after virus inoculation ranged from 82% to 
85%. Eggs collected at 5 WPI had a relatively low hatchability (75%). Each batch of chicks 
was daily monitored for viremia and fecal shedding by the nested RT-PCR. Bile and liver 
samples collected from all chicks necropsied at 7 days of old were also subjected to the 
nested RT-PCR. However, the hatched chicks were negative for avian HEV infection.          
Gross hepatic lesions 
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Chickens necropsied weekly from Groups 1 and 2 had no visible gross subcapsular 
hemorrhage, which is the characteristic liver pathological change after experimental avian 
HEV infection (Billam et al., 2005). None of chicks necropsied at 7 days of old had 
observable liver abnormality.  
Discussion 
Avian HEV was isolated in the United States (Haqshenas, et al., 2001; Huang, et al., 
2002) from chickens with HS syndrome, an emerging chicken disease
 
in North America 
(Riddell, 1997; Ritchie & Riddell, 1991). This virus can be detected in liver tissues, bile, 
sera, feces from infected chickens (Haqshenas, et al., 2001; Huang, et al., 2002; Sun et al., 
2004; Billam, et al., 2005). In this study, we found that avian HEV RNA is detected by RT-
PCR in eggs from chickens experimentally infected with avian HEV (Fig. 1). Sequencing 
results confirmed that the virus detected in egg white is originated from the virus used for 
inoculation. Most importantly, we demonstrated that the virus in the egg white is still 
infectious as evidenced by the detection of viremia and fecal virus shedding in chickens 
inoculated with the PCR-positive egg white samples (Table 1). Seroconversion and slight 
elevation of serum level of LDH were also detected in the chickens inoculated with PCR-
positive egg white sample, although they occurred later than those in chickens inoculated 
with an avian HEV infectious stock (Fig. 2, and Fig. 3).  
Avian HEV is highly prevalent in the United States as anti-avian HEV antibodies 
have been found in approximately 71% of the chicken flocks in 5 states (Huang et al., 2002). 
Although we previously showed that avian HEV failed to infect 2 rhesus monkeys (6), avian 
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HEV does have the ability to cross species barriers and infect turkeys (Sun et al., 2004). Until 
now, there is no direct evidence as to whether avian HEV can infect human or not.  
Chicken eggs are one of the most popular and highly nutritious foods, and eating raw 
eggs are common in many parts of the world (Doorduyn et al., 2006; Lievonen et al., 2004; 
Shiferaw et al., 2002; Sin et al., 2000). A multistate surveillance conducted in the United 
States between 1995 and 1996 had found that as high as 50% of the responders ate 
undercooked or raw eggs and  more than 60% did not wash hands after cracking raw eggs and 
this habit has kept unchanged for years (Yang et al., 1998; Sara, et al., 2002). In addition, 
several foods contain raw eggs, such as meringue, hollandaise sauce, cookie dough, 
homemade mayonnaise, and Caesar salad dressing (Mazurek et al., 2005; Laura 2006). The 
finding of the infectious avian HEV in egg white and the significant percentages of 
individuals eating raw and undercooked eggs raised a question as to whether or not infected 
chicken eggs could be a potential source for the observed high seroprevalence of IgG anti-
HEV in the general population in the industrialized countries, including the United States 
(Purcell & Emerson, 2005). Even if avian HEV does not infect humans, repeated exposures 
to the same foreign microorganism could cause the production of anti-HEV IgG antibody, 
especially since avian HEV could survive acidic stomach environment after its oral 
inoculation into chicken (Billam et al., 2005). 
We have previously identified common antigenic epitopes in the ORF2 protein 
between avian HEV and human HEV (Guo et al., 2006). Western blot and ELISA results 
indicated that the avian HEV ORF2 capsid protein reacted with antisera against human HEV. 
Convalescent sera from SPF chickens experimentally infected with avian HEV also reacted 
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with the recombinant ORF2 capsid proteins of human HEV (Haqshenas et al., 2002). 
Therefore, it is possible that the IgG anti-HEV antibodies detected from healthy individuals 
in the United States and other industrialized countries could be the results of repeated 
exposures to avian HEV through the consumption of raw chicken eggs. Further studies are 
warranted to definitively determine if there is a correlation between IgG anti-HEV 
seroprevalence and egg-eating habits in humans.  
Vertical transmission of human HEV was first reported in India, where six of eight 
infants from infected mothers had HEV infection (Khuroo et al., 1995). Approximately two-
thirds of the infected pregnant women could have preterm deliveries (Kumar et al., 2004), 
and approximately 8% of HEV-RNA positive infants born to the infected mothers developed 
acute clinical disease that could cause early neonatal deaths (Kumar et al., 2001). The 
mortality rate among the HEV-infected pregnant women is up to 20% (Purcell & Emerson, 
2001), however attempts to experimentally reproduce the severe hepatitis in pregnant rhesus 
monkeys and pregnant sows were unsuccessful and the infected pregnant animals failed to 
transmit virus to newborns (Tsarev et al., 1995; Kasorndorkbua et al., 2003).  
Although avian HEV could be transmitted to egg white, it was not able to establish 
the vertical transmission, as no virus was detected in any samples collected from a total of 60 
hatched chicks. Shivaprasad et al (1995) reported that the agent associated with the HS 
syndrome could not be isolated from chicken embryos with conventional routes of egg 
inoculation (Shivaprasad et al., 1995). In contrast, we previously showed that avian HEV 
could be successfully propagated in embryonated chicken eggs by intravenously 
inoculating100 GE of avian HEV into 9-day-old embryonated chicken eggs (Meng et al., 
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2006). Avian HEV was detected in bile and liver samples collected from hatched chicks 
necropsied at 2 to 3 days of age with very high GE titer (Meng et al., 2006). The virus had 
also been continuously detected in feces for at least 8 days after hatch.  
In this study, instead of inoculating embryonated eggs, we directly inoculated each 
hen with 4000 GE of avian HEV, collected their eggs for hatching and then monitored the 
presence of virus in hatched chicks. In the five positive egg white samples from eggs laid by 
chickens inoculated with 1000 GE of avian HEV, two had an avian HEV genomic titer of 
100 GE/ml and three had a titer of ≥1×10
3
 GE/ml. A typical chicken egg contains more than 
10 ml white, thus avian HEV virus can enter the egg white with a relatively high dose to 
infect chicken embryos and chicks. We proved that the virus in egg white remains infectious, 
but the stability of the infectivity during the hatching process is not known. Our result from 
this study that no virus could be detected in samples from the hatched chicks and our 
previous results (Meng et al, 2006) that avian HEV could be detected in samples from the 
chicks hatched from eggs that were intravenously inoculated with avian HEV at 9 days of 
embryonation (Meng et al., 2006) suggested that the infectivity of avian HEV in eggs before 
or at 9 days of embryonation has decreased to such an extent that the virus is unable to 
transmit further to chicks. The results from this study should help understand the 
transmission of HEV in humans.   
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Table 1. Detection of avian HEV RNA in sera, fecal swabs and bile samples from inoculated 
chickens. 
No. of positive sera (fecal swabs) / total no. tested at indicated WPI 
No. of positive bile samples / total no. tested at indicated WPI Chicken groups 
0 1 2 3 4 5 
Group 1
*
 0(0)/18 
ND
§
 
0(0)/18 
0/3 
0(0)/15 
0/3 
10(8)/12 
3/3 
9(9)/9 
2/3 
6(5)/6 
2/6 
Group 2
†
 0(0)/18 
ND 
0(0)/18 
0/3 
0(0)/16 
0/3 
0(0)/12 
0/3 
0(0)/12 
0/3 
0(0)/6 
0/6 
Group 3
‡
 0(0)/2 
ND 
2(2)/2 
 ND 
2(2)/2 
ND 
2(2)/2 
ND 
2(2)/2 
ND 
2(1)/2 
ND 
 
*, chickens were inoculated with an egg white sample positive for avian HEV RNA by RT-
PCR; 
†
, chickens were inoculated with normal egg white negative for avian HEV; 
‡
, only the 
two hens were inoculated with an avian HEV infectious stock; 
§
, not done. 
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Table 2. Hatchability of eggs collected from hens experimentally infected with avian HEV 
No. of eggs unhatched 
Batch* No. of eggs hatched  Hatchability 
Dead embryos No fertilization 
Fertility 
-1 10 83% 2 0 100% 
1 11 85% 2 0 100% 
2 9 82% 1 1 91% 
3 11 85% 1 1 93% 
4 10 83% 2 0 100% 
5 9 75% 2 1 92% 
 
*: Eggs collected during the same week period were hatched in a batch before (-1 batch) and 
after (1 to 5 batch) hens were intravenously inoculated with an avian HEV infectious stock.  
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Figure 1: Detection & GE titration of avian HEV RNA in egg white. Panels A and B: 20 egg 
white samples were tested for the presence of avian HEV RNA by a nested RT-PCR assay 
that amplifies a 221 bp region in the avian HEV helicase gene. M: DNA marker; lane 1 to 20 
are egg white samples #1 to #20, respectively. Panels C, D, and E: Genomic equivalent titer 
of avian HEV RNA determined by semi-quantitative RT-PCR. Total RNA was extracted 
from 100 µl of undiluted and 10 fold serially diluted (from left to right) egg white samples 
and amplified by the nested RT-PCR. Panel C: egg white sample #4; Panel D: egg white 
sample #16 (lane1-5) and #17 (lane 6-10); Panel E: egg white sample #13 (lane1-7) and #14 
(lane 8-14).      
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Figure 2: Seroconversion to avian HEV IgG antibodies in chickens experimentally 
inoculated with PCR-positive egg white and with an avian HEV infectious stock.  Sera 
from 14 chickens continuously monitored throughout the 5-week study were diluted at 1:100 
and tested for the presence of anti-avian HEV ORF2 antibodies by ELISA. Recombinant 
avian HEV ORF2 antigen was coated at 100 ng/well on the ELISA plates. Each point 
represents the mean values (±S.E.M.) of the OD 490 nm obtained from duplicate ELISA 
results. Chickens #13 to #18 were inoculated with egg white sample #13 that is positive by 
PCR for avian HEV RNA. Chickens #31 to #36 were inoculated with a normal egg white 
sample that is negative for avian HEV RNA. Chickens #37 and #38 were inoculated with an 
avian HEV infectious stock as positive controls. 
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Figure 3: Serum level of LDH in infected and control chickens. The log mean LDH 
values at each WPI were generated from 6 continuously monitored chickens from Group 1 
that were inoculated with an egg white sample #13 that was positive for avian HEV RNA, 6 
continuously monitored chickens from Group 2 that were inoculated with a normal egg white 
sample that is negative for avian HEV RNA, and 2 continuously monitored hens from Group 
3 that were inoculated with an avian HEV infectious stock. *, Statistical significance (P 
≤0.05). 
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CHAPTER 7. GENERAL CONCLUSION 
General discussion 
Avian HEV infection is associated with the HS syndrome in chickens, an emerging 
disease in North American [1-4]. It has been demonstrated that avian HEV infection in 
chickens can serve as a valuable homologous small animal model for studying human HEV 
pathogenesis [5]. Avian HEV recombinant ORF2 protein was expressed in bacterial cells and 
used as target antigen for the detection of anti-avian HEV infection [2, 5-8]. But detailed 
analysis of this major viral antigen is lacking. In this thesis, the protective function of ORF2 
protein of avian HEV and its epitope composition have been investigated. Since vertical 
transmission of HEV in both pregnant non-human primates and swine failed [9, 10], vertical 
transmission of avian HEV in chickens was also evaluated in hope of establishing a model to 
study some aspects of vertical transmission of human HEV.  
Current ELISA methods using the recombinant ORF2 protein for HEV serological 
diagnosis can not differentiate avian HEV from swine HEV and possible human HEV 
infections, due to the cross-reactivity between the ORF2 proteins [6, 11]. In the first study, 
we found that at least one B-cell epitope in
 
the antigenic domain I is shared among avian, 
human and swine
 
HEV capsid proteins, and that at least one epitope in domain IV is shared
 
between avian and human HEVs. However, epitopes in domain II
 
are unique to avian HEV. 
Thus, peptide 8 from domain II could be used for the differential diagnosis of avian HEV 
infection by ELISA. Peptide 8 combing with peptide 1 and 4 can be used for differential 
diagnosis of human HEV infection. Peptide 1 combining with peptide 8, but not peptide 1 
combining with peptide 4 can be used for differential diagnosis of swine HEV, as some field 
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swine HEV positive swine sera can react with peptide 4. It should be pointed out that a 
sufficient number of sera samples from different regions are needed for further evaluation of 
these peptide ELISAs before their actual applications. 
 In the second study, we demonstrated that chickens immunized with avian HEV 
ORF2 recombinant protein were able to produce high level of anti-ORF2 antibodies and were 
protected from avian HEV infection and/or the development of hepatitis. These findings 
showed that avian HEV ORF2 protein can be used as candidate vaccine for prevention of the 
emerging chicken HS disease. They also suggested avian HEV ORF2 protein is the major 
viral antigen that targeted by chickens, like its counterpart of human HEV [12-15]. Currently, 
virulent or very virulent strain of avian HEV has not been isolated or probably has not 
emerged yet [2], thus we couldn’t know whether the recombinant avian HEV ORF2 antigen 
used in this study can provide protection against virulent strains, although studies from 
human HEV had demonstrated that the immunization of ORF2 protein can provide protection 
against both homologous and heterogeneous challenges [16, 17] and convalescent sera 
induced by one genotype of human HEV can neutralize all four genotypes [14, 18, 19] and 
also one monoclonal antibody against human HEV ORF2 protein can neutralize at least two 
HEV genotypes [14].  
Since neutralization epitope is the major component that determines the efficiency of 
human HEV ORF2 protein vaccine [12-14] and avian HEV is genetic and antigentic related 
to human HEV, avian HEV ORF2 protein probably also contains protective neutralization 
epitopes. Indeed, two independent neutralizing epitopes on avian HEV ORF2 capsid protein 
were identified in the third study by using neutralzing Mabs and recombinant proteins. This 
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finding provided evidence that protection against avian HEV infection by immunization with 
avian HEV ORF2 protein was probably due to the induced neutralizing antibodies. Although 
in the first study, we identified at least three epitopes on avian HEV ORF2 proteins, but our 
unpublished data showed neither of them is neutralizing epitope. Peptides containing these 
epitopes could not react with neutralizing Mabs, further supporting this conclusion. 
In the fourth study, we are first to report the unexpected finding that avian HEV can 
be detected in eggs collected from chickens experimentally infected with avian HEV by 
nested RT-PCR. We further proved avian HEV in egg white is infectious. The finding of the 
infectious avian HEV in egg white and the fact that eating raw eggs is popular [20-24] and 
avian HEV is still of possible zoonotic concern prompted us to consider avian HEV infected 
eggs a new possible source of HEV seroprevalence in general population [25]. Although 
avian HEV could be transmitted to egg white, it failed to successfully establish the vertical 
transmission route, suggesting the infectivity of survived virus in egg white during hatch 
process is attenuated or completely lost.  
Recommendations for future research 
Although the combinations of peptides 1, 4 and 8 can be potentially used for 
differential diagnosis of HEV infection, the sensitivity of these peptide assays has not been 
evaluated. It also should be aware that synthetic peptides are such small molecules that may 
be not stable. The storage concentration, temperature and duration can significantly affect the 
peptide ELISA result. Conjugation of peptides with carrier molecules, like keyhole limpet 
hemocyanin (KLH) can be an approach to stabilize these peptides, but whether the 
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conjugation will affect the specificity and sensitivity of peptide ELISA assays needs to be 
tested.  
Two different neutralization epitopes unique to avian HEV ORF2 protein were 
identified with four Mabs. However, it is likely that other neutralization epitopes not 
recognized by the four established Mabs may exist. These neutralization epitopes could be 
conserved among human and animal HEVs. Identification of these neutralization epitopes 
may thus provide a theoretical basis for applying avian HEV ORF2 protein as a candidate 
vaccine for prevention of human and animal HEV infections.  
The fact that avian HEV in egg white is highly infectious and the possibility of avian 
HEV cross infection in human make it prudent to perform a large scale survey of the presence 
of infectious avian HEV in commercial eggs and investigate the egg eating habit in anti-HEV 
positive population. The obtained results may potentially provide further evidence for the 
possible food-borne zoonotic transmission of avian HEV.  
To date, HEV has been found to be vertically transmitted only from pregnant mothers 
to fetuses causing death or disease in new-born infants [26-29]. Establishing an animal model 
for vertical transmission study would benefit the understanding of vertical pathogenesis. 
Thus, the continuing search of animal strains of HEV and investigating their vertical 
transmission route are warranted.    
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